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“Getting a new idea adopted,  
even when it has obvious advantages, 
 is often very difficult.” 
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Abstract	
Health sector faces increasing pressure to provide quality service with limited 
budget. Adoption of innovative technology is a powerful solution to the problem. 
Technology adoption encompasses a range of inter-related complexity between technical, 
human and organizational factors involving multiple stakeholders. Different technologies 
may be adopted through different pathways in a specific healthcare system. There is not 
much empirical data and theoretic findings regarding how innovative technology is 
adopted in Norwegian specialist health care.  
Personalized Cancer Medicine (PCM) is an innovative technology transforming 
cancer patients’ care, which is currently adopted in Norway. PCM adoption represents a 
typical case for technology adoption in the Norwegian specialist health care and it is 
worth documenting and analyzing.  
We have conducted a descriptive and exploratory single qualitative case study 
about this contemporary project in its real-life context. Through conducting in-depth 
interviews with stakeholders, participating meetings/debates, and analysis of documents 
and scientific publications, we provide an in-depth longitudinal description of PCM 
adoption in Norway. 
In this thesis, we find evidence supporting that new technology adoption in 
healthcare is in response to both exogenous and endogenous stimulus and actions. The 
user perceived usefulness of this technology for resolving an important societal problem 
stays centrally for the possibility of adoption. The nature of the technology concerned and 
its intersecting with the specific local adoption system largely influence the adoption 
trajectory. Researchers with high entrepreneurial-orientation (EO) in healthcare system 
have an indispensable role in decision-making, strategy articulation and implementation 
as both managers and technology champion. A top-down, coordinated program with 
public fund can be an effective strategy for adoption of innovation towards a high-end 
use in the Norwegian decentralized healthcare system. Facilitators and barriers for PCM 
adoption are identified. This extensive descriptive information may be useful for 
portraying a rather complete picture to inform further managerial actions for PCM 
implementation. 
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1. Introduction	
Health sector faces tremendous pressure to provide better service with less money. 
Adoption of innovative technology is a powerful way to enhance productivity and 
efficiency, thus providing a remedy to tackle the challenge. There is however insufficient 
empirical evidences and theoretical researches regarding the adoption of innovative 
technologies in the Norwegian healthcare system. Personalized Cancer Medicine (PCM), 
which transforms cancer patients’ care to an individualized treatment based on the 
patients’ genomic information, is one of the innovative technologies currently adopted by 
the Norwegian health care system. In this study, we present empirical evidence through 
studying the process of PCM adoption to provide information for managerial actions for 
future PCM technology implementation and shed light for further theoretical research.          
1.1 Background	about	the	Norwegian	Healthcare	System		
Better and equitable health is a global aspiration. The ultimate goal of any health 
care system is to better the health for all. A healthcare system is defined, according to 
The World Health Organization (WHO), as “the arrangement of all organizations, 
institutions and resources devoted to produce actions whose primary intent is to improve 
health”. Healthcare systems vary all over the world, but with three elements common to 
all health care systems: financing, reimbursement, and production or delivery.  
Norwegian health care system is mostly publicly funded through tax-based 
funding and has a large proportion of public governance. The central government 
provides grants to the counties who reallocate finance to the hospital sector. The state-run 
National Insurance Scheme (NIS), created in 1967, offers public insurance against 
individual medical expenses (fees-for-service) for ambulatory care provided by hospitals 
and private practitioners. All public hospitals run by four Regional Health Authorities 
(RHA) owned by the Ministry of Health and Care Services (Hagen and Kaarbøe, 2006). 
The proportion of private actors is relative small, and few people have private health care 
insurance. Norwegian healthcare has a goal of equity in health without compromising 
universalism. All citizens are eligible for treatment free of charge in the public hospital 
system and all citizens have the right to Free Hospital Choices (The Patients’ Rights Act, 
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1999). The Norwegian Health Care System was ranked number 11 out of 190 nations by 
the overall performance in a report from WHO (world health report, 2000).  
The healthcare is a substantial part of the public sector in Norway.  According to 
statistics, nominal general governmental expenditures in the healthcare in Norway for the 
year 2010 was around 17 % of total costs (ssb.no, 2010) and was ranked as the second 
highest expenditure among all the sectors in Norway. Some of the recent researches show 
that this high cost is largely due to the relatively lower productivity in specialist health 
care as compared to other Nordic countries (Kittelsen, 2009).  The healthcare expenditure 
is expected to be continuously increasing in the next couple of decades, which imposes a 
pressure on the country’s welfare sustainability. Such forecasts bring out the questions on 
how to use the available resources to provide the population with more/better health care 
services through enhancing productivity and efficiency, so that hospitals are able to 
produce more output with the same amount of inputs. 
Adoption of innovative technology is a powerful way to enhance productivity and 
efficiency. Innovative technology in healthcare has significantly enhanced accuracy and 
effectiveness of the diagnosis and treatment (Lemieux-Charles, 2006). However, despite 
of rich evidence-based technological advances, there is moderate progress in technology 
adoption in healthcare comparing to other industries (Lemieux-Charles, 2006), which is 
partly due to the great organizational complexity in healthcare system.  
Within the complex, decentralized Norwegian healthcare, how an innovative 
technology can be adopted in specialist health care for the whole population? There are 
not many theoretical and empirical researches focusing on this aspect. Personalized 
cancer medicine represents a transformation on modern healthcare and provides a good 
context for the study of this question.  
1.2 Introduction	to	the	Case	of	Personalized	Cancer	Medicine	(PCM)		
This section introduces the context where the case of PCM is embedded in and 
defines the frame for this study. 
3 
 
1.2.1 The	Biology	Context	
A gene carries genetic information of a living organism, which can be inherited 
by the next generation. In human beings, a gene is a sequence of deoxyribonucleic acid 
(DNA) packed in a chromosome. This DNA sequence can be transcribed into RNA 
(another type of nucleic acids) and the corresponding protein will be synthesized based 
on the RNA sequence. Protein is the functioning unit of our body. Therefore, genetic 
information flows following a DNA--RNA--protein dogma. Often a change in DNA 
sequence - known as mutation- will lead to a change in its resulting protein and leading to 
a malfunctioning protein. The accumulation of the critical changes in DNA and thus 
malfunctioning protein will lead to diseases, among those the cancer. In worst case, a 
single change in DNA and protein can cause diseases. Every cancer patient has a unique 
combination of DNA mutations-every tumor has various mutations and the same gene 
can be mutated in different tumors. When critical mutations are inherited, next 
generations will have increased prognosis to certain diseases. Accumulation of molecular 
abnormalities in tumorigenesis has allowed further sub-classification of many cancer 
types (Pleasance et al., 2009).    
1.2.2 Current	Cancer	Medicine	
The current cancer treatment is generally practiced at a principle of one-drug-for-
all- patients, although some patients may receive drugs targeting the mutation on a single 
gene. In principle, most modern cancer molecule drugs are designed to target and block 
the malfunctioning mutated protein, thus controlling cancer progression. However, when 
the drugs are used at one-for-all principle, the drug will not work efficiently for most 
patients and might cause unnecessary side-effects, as most patients get a drug targeting a 
protein in which there is no mutation and not the cause of the disease for the patient. This 
traditional practice is thus not for the patients’ best benefit and costs unnecessarily extra 
for societal healthcare. This traditional practice needs to be improved. With personalized 
medicine, we can pinpoint at the exact gene mutations, that are the disease causes, and 
specific drugs targeting these mutations can be administrated for the best patient benefit. 
Some scholars argue that within the next 20 years, the advances in cancer medicine could 
transform cancer from a death warrant to long-term health management (RIFAT et al., 
2007).       
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1.2.3 The	Personalized	Medicine	and	Technology	
The modern healthcare stands at the transformation threshold from the traditional 
disease event focus to Predictive, Preventive, Personalized and Participatory Medicine 
(P4M) for meeting each individual’s specific health needs, as coined by Dr. Hood eight 
years ago (Hood, 2004). This transformation is rooted from the well-established principle 
that each individual is born with unique inherited genetic characteristics, while a great 
deal of individual’s genome is shared by all humans. The variations result in each 
person’s unique susceptibility and resistance to various diseases. The transformation to 
P4M is facilitated rapidly by advances in science and technology. Innovative 
tools/technologies for P4M have been developed, which enable the prediction of health 
risk, quantifying disease development and providing guidance to the targeted therapeutic 
approaches (Hood et al., 2004). P4M focuses on the integrated diagnosis, treatment and 
prevention of disease in individual patient by integration of new approaches to disease 
diagnosis, new measurement and visualization technologies, computational and 
mathematical tools. P4M provides new abilities to detect disease at an early stage; stratify 
patients into groups that enable the selection of optimal therapy, thus reduce adverse drug 
reactions (Hood, 2008). With exemplary evidence-based knowledge and know-how, P4M 
has now been approved in practice and envisioned as a major revolution in healthcare, 
which will over the next few years replace the traditional reactive mode of medicine-
where we wait until the patient is sick before responding. When this is aligned with 
appropriate healthcare resources, it can be used for any health objectives ranging from 
health promotion to chronic disease management. There have been many initiatives for 
developing P4M at national, regional and sector levels across the world, such as in US, 
Canada, UK and Netherland.  
For the simplicity, personalized medicine is defined as “a form of medicine that 
uses information about a person's genes, proteins, and environment to prevent, diagnose, 
and treat disease” (Hood, 2008). Implementation of personalized medicine in clinic 
requires an Integrated Health-Information Platform consisting of a sequencing 
technology and highly integrated bioinformatics software (HIBS). With this HIBS, the 
patients’ DNA sequence data obtained from the sequencing instrument can be assembled; 
disease-cause gene can be identified.  This information will direct clinicians for diagnosis, 
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prescription and patient follow-up, and a patient-centered personalized medicine is 
practiced at molecular level. 
1.2.4 The	Personalized	Cancer	Medicine	(PCM)	Status	Quo	in	Norway		
In 2010, there are 28271 new cancer cases registered in Norwegian cancer registry. 
The incidence rate has increased by 7 per cent for men and 3 per cent for women from the 
past five-year period (2001-2005) to the current one (2006-2010) (Cancer registration, 
2012). Cancer research is the first priority according to Norwegian research council. In 
order to bring the personalized medicine  into reality to benefit all the citizens, cancer 
treatment is the initial strategic focus of P4M practice in Norwegian healthcare. The 
Norwegian government has recently set up a temporary financing scheme for this purpose 
(Norwegian Health directorate, 2012). A total governmental investment of 75 million 
NOK has been placed at the first stage for PCM technology adoption towards both clinic 
and research use in hospitals.  
The vision is to develop a national platform providing knowledge-based 
individualized cancer therapy, encompassing screening, diagnosis, prognosis, prediction 
of treatment efficacy, patient follow-up after treatment, early detection of recurrence and 
stratification of patients into cancer subgroup categories for target treatment. This regime 
will allow physicians to see early warning signs of malignancies and take early action for 
targeted therapy based on patients’ genomic information. People could adjust their 
lifestyles accordingly to prevent disease.  
This technology is disruptive to Norwegian healthcare in the way that it applies an 
innovative technology to the field of cancer patient management, namely it is a new 
clinical use of this innovative technology in Norwegian healthcare. This will transform 
the traditional disease event-focused medical care to a personalized and preventive care. 
This is a coherent model of health prevention, cancer avoidance and targeted treatment, 
which challenges so much of the conventional wisdom and institutional complacency and 
requires engagement at multiple levels of health care system—from policy maker, 
managers, and scientists to physicians.    
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Currently, PCM has been adopted in four national health regions with established 
sequencing technology platform in OUS/UiO, UiB, NTNU and UiT. Clinical sequence 
data has been collected through pilot clinical trials in collaboration between clinicians 
and scientists in the regional sequencing platform. This data will compose a national 
mutation database and register in cancer registry. This database serves as a valuable 
dataset for further cancer biology research and drug discovery.    
In this study, we have followed the technology adoption over time (from the 
earliest initiative in 2011 to 2013) in Norwegian healthcare system, with focus on 
exploring some particular aspects of the adoption lifecycle in detail. All the national 
events related to PCM adoption are included in this study and collectively defined as “the 
case for personalized cancer medicine in Norway”. Due to the time limitation, the study 
will be focused only in Oslo region. An expansion of this study to include all four health 
regions in the Norway would be left for future exploration.     
1.3 Research	Questions	and	Objectives	
1.3.1 Research	Questions	
The national strategic goal of personalized cancer medicine (PCM) is to provide 
evidence-based, patient benefit and cost-effective treatment to cancer patients inhabited 
in Norway based on the patient’s genomic information. PCM innovation is complex 
involving multi-disciplined collaboration of major constitutions in healthcare (patient, 
clinicians, administrators and researchers) and partnership of disciplines (i.e. 
bioinformatics, biologist, information technologist, statisticians, physicians) and 
organizations (i.e. drug and device firms, healthcare agencies, information technology 
firms and academic medical community)(Chiang A. , 2011 and Snyderman R. 2012). Due 
to the range of inter-related complexity between technical, social and organizational 
factors, adoption and implementation of innovative technology in healthcare is 
notoriously difficult. The adoption is not a straightforward linear process, but rather a 
dynamic one, as the technical, social and organizational factors are gradually aligned (or 
not) over time in the context (Cresswell and Sheikh, 2012). Generally, adoption of a 
technology requires reinvention of the technology or a specific model under specific 
cultural and organizational context. Currently there is no available complete model that 
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Norwegian health care system can apply from. In addition, there has not been much 
theoretical research on the Norwegian health care system regarding innovative 
technology adoption.  
This PCM program represents a typical case for technology adoption in 
Norwegian specialist health care. It is a case capturing the circumstances and conditions 
of a common situation and could be functioning as a test ground for theoretical 
propositions and model building. It is of timely importance to investigate how this 
innovative technology-personalized cancer medicine is adopted in Norwegian 
healthcare? An extensive collection of such descriptive information will be useful for 
portraying a somewhat complete picture, which facilitates further managerial actions. The 
experiences from this study may be informative for the future technology adoption. Other 
specific research questions include:  
 How various technical, human, social and organizational factors are involved and 
influencing technology adoption in Norwegian healthcare? 
 What aspects of Norwegian healthcare are unique and how do these influence 
PCM technology adoption? 
 How the inter-interaction of technical, human, social and organizational 
dimensions evolved along the process? How are they aligned (or not) until now? 
1.3.2 Research	Objectives	
Based on a thorough study of the PCM adoption in Norwegian healthcare system, 
this study is aiming: 
 To describe a model for innovative technology adoption in Norwegian healthcare  
 To identify the key technological and organizational facilitators for successful 
adoption of PCM technology in Norwegian healthcare  
 To identify the barriers or missing links for technology adoption and diffusion in 
Norwegian healthcare 
 To provide a basis for interventions (i.e. training and model refinement) for 
managerial act to increase user acceptance and more efficient technology adoption 
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2. Theoretical	Grounding	
This section presents literature review on the following topics: innovation and 
entrepreneurship, technology adoption, technology acceptance model, fit of human, 
organization and technology, as well as stakeholder theory. These theories altogether set 
up a framework for analyzing the innovative technology adoption in healthcare system. 
Some propositions are developed based on these theories.  
2.1 Innovation	and	Entrepreneurship	
Scholars have different views about innovation (Mises, 1949, Schumpeter, 1941, 
Bower and Christensen, 1995). According to Schumpeter (1941), innovation is the 
critical driver of economic change. He classified innovation into the following five 
‘types’: new products, new methods of production, new sources of supply, the 
exploitation of new markets and new ways to organize business. Generally speaking, 
Schumpeter refers innovation as the new combinations resulting in the changes for the 
product production and function. This concept of innovation is more or less restricted to 
radical changes with a great impact on the industry sectors or business cycles. The minor 
day-to-day technical improvements are regarded as less important. Disruptive technology 
is a type of radical changes. A technology is regarded as disruptive when its utilization 
generates products with different performance attributes that may not have been valued 
by existing customers (Bower and Christensen, 1995). These new values can be created 
through the “different” nature of an existing technology or a radically new technology. 
Bower and Christensen favor the view of “different” nature of technology, emphasizing 
that they may not be radically new from a technology point of view, but have superior 
performance in the critical dimensions of customers’ value (Bower and Christensen, 
1995). While others argue the radical newness is an important element in this definition 
(Lynn et al., 1996). Despite the existence of these two views, disruptive technology will 
change the unusual products/technology paradigms and enables discontinuous products, 
process of services to provide customer-perceived exponential values (Lynn et al., 1996, 
Veryzer Jr, 1998). 
These technological innovations thus give capitalist economies the peculiar 
dynamics through a process of "creative destruction", which could provide better results 
than the invisible hand and price competition.. Innovation adoption will mean the process 
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of bringing inventions into use. As perceived by Rogers (Rogers, 2008), adoption is “a 
decision to make full use of an innovation as the best course of action available,” and the 
process elements of adoption occur before or after the decision. 
In healthcare, innovation is defined as those changes that help health practitioners 
focus on the patient by helping healthcare professionals work smarter, faster, better and 
more cost effectively (Thakur et al., 2012). Adoption and implementation of those best-
demonstrated successful practices will change the performance of the organization. 
However, adoption of innovation in healthcare system is extremely difficult, because this 
process not only depends on the stakeholders’ perceived consensus benefits of the 
innovation, but largely relies on the contextual environment where the adoption should 
occur (Atun et al., 2010). The context may be external environment, such as government 
regulations, market trend and the safety compliance; or internal environment, such as 
organizational structure and culture, top-management decision-making process 
(Yarbrough and Smith, 2007, McFarland and Hamilton, 2006). 
Entrepreneurship is a fast growing field and the entrepreneur is widely accepted 
as a fundamental economic agent driving economic development (Mises, 1949, 
Schumpeter 1941). In a broad definition, entrepreneurship is an activity that involves the 
discovery, evaluation, and exploitation of opportunities to introduce new goods and 
services, ways of organizing, markets, process, and raw materials through organizing 
efforts that previously had not existed (Venkataraman, 1997; Shane and Venkataraman, 
2000). All “those situations in which new goods, services, raw materials, and organizing 
methods can be introduced and sold at greater than their cost of production” are regarded 
as opportunity and treated as objective phenomena. Research fields within how the 
entrepreneurial role should be incorporated into economy and strategy and how an 
entrepreneurial opportunity is identified remain hot topics.  
In Schumpeter’s theory, entrepreneurial activities are interconnected with 
dynamics of innovation (Hagedoorn, 1996, Schumpeter, 1941). Schumpeter proposed 
that in the period of entrepreneurial capitalism, entrepreneurial activity is seen as the third 
factor of production in addition to the land and labor. “The” entrepreneur is the individual 
who carries out the new combinations and introduces the innovation, hence regarded as 
the only agent for economic change. Entrepreneurs are by definition neither inventors, 
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capitalists nor a social class, although they all can be combined in one person. While in 
the period of modern trustified capitalism, agents that drive innovation and the economy 
are large companies, which have the resources and capital to invest in research and 
development. In the large companies, “the entrepreneur is not necessarily and 
independent economic agent, but can be an employee of the large company with an 
entrepreneurial function” (Hagedoorn, 1996, Schumpeter, 1941). This entrepreneurial 
function is often filled cooperatively at large scale. In another word, the role of the 
entrepreneur is analyzed in terms of the function in the large company, and not 
necessarily at a physical person (Hagedoorn, 1996). In modern capitalism, the 
entrepreneurial activities can thus range from a single-person to a collective 
entrepreneurial function in large companies. The latter can be referred to intrapreneurship, 
where employee takes initiatives in organizations to undertake something new, without 
being asked to do so. Intrapreneur integrates risk-taking and innovation approaches to 
creatively transform an idea to a profitable venture and better performance within the 
organizational environment.  
Knightians describe entrepreneurship as the exercise of judgment regarding an 
uncertain future. The entrepreneur’s role is to arrange or organize the capital goods 
he/she owns. Hence, opportunities are manifested in entrepreneurial action, namely the 
exercise of judgment over the arrangement of heterogeneous assets. Resource owners, by 
the nature of ownership, possess fundamental judgment rights and are treated not as 
passive suppliers of capital, but as critical decision makers. 
Foss and Klein describe entrepreneurship as a creative team act in which 
heterogeneous managerial models interact to create and arrange resources to produce a 
collective output that is creatively superior to individual output (Foss et al., 2008, Foss 
and Klein, 2008). He emphasizes that entrepreneurial judgment and the recognition and 
enactment of opportunities may be derived from social processes such as dynamic 
interactions among team members’ heterogeneous mental models. In contrast to 
Schumpeter and Knight, Foss proposed a subjectivist approach to entrepreneurship in 
which the team, rather than the individual entrepreneur, is the unit of analysis and the 
team’s capital and resources are the key determinants of entrepreneurial activity (Foss et 
al., 2008), thereby bridging up the entrepreneurship and strategic management.  
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There are different views about entrepreneurial opportunity. Kirzner and others 
regarded the entrepreneurial opportunity as an entirely exogenous arbitrage objective 
phenomenon and is waiting to be discovered by alerted people. In this discovery theory, 
Kirznerian offer no theory of how opportunity is discovered and who identifies it; 
whereas in creation theory, opportunity is not an objective phenomena formed by 
exogenous shock to an industry or market. Rather, they are created endogenously by 
actions and enactment of entrepreneurs exploring ways to produce new products or 
services (Alvarez and Barney, 2007).   
Entrepreneurial orientation (EO) is one of the most important and established 
concepts within the field of entrepreneurship. EO is generally consisted of the five facets: 
competitive-aggressiveness, risk-taking, innovativeness, proactiveness, and autonomy 
(Lumpkin and Dess, 1996). EO provides critical insights into questions of organizational-
level strategy and performance. The attitudes and behaviors related to EO have been 
positioned as organizational phenomena that capture firm-level entrepreneurial patterns 
and processes (e.g Lumpkin & Dess, 1996, 2001). Walse and others have suggested that 
the manifestation of EO across organizational sub-units, from large strategic business 
units to small individual departments, also matters (Wales et al., 2011 ). EO is manifested 
within firms such that entrepreneurial attitudes and behaviors “pervade the organization 
at all levels” (Covin and Slevin, 1991). 
2.2 Technology	Adoption		
Technology adoption generally refers the process by which an innovative 
technology is selected for use and then incorporated into daily use by an individual or an 
organization. This adoption normally progresses along sequential stages, proposed by 
Bohlen, Rogers and others (Beal and Bohlen, 1957, Rogers, 2008), of awareness, interest, 
evaluation and trial. Through this process, the individual or organizations make decision 
to adopt or reject the technology. The process of adoption over time follows a classical 
normal distribution or "bell curve", as figure 1 (Rogers, 2008). The adopters can be 
categorized as innovators, early adopters, early majority, late majority and laggards, 
according to the demographic and psychological characteristics of defined adopter groups. 
These five categories are summarized: 
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 Innovators –more educated, more prosperous and risk-oriented 
 Early adopters – younger, more educated, tended to be community leaders 
 Early majority – more conservative but open to new ideas, active in community 
and influence to neighbors 
 Late majority – older, less educated, fairly conservative and less socially active 
 Laggards – very conservative, oldest and least educated 
The first group of people to use a new product is "innovators," and the last group 
to eventually adopt a product is called "laggards." Each adopter's willingness and ability 
to adopt an innovation depends on his awareness, interest, evaluation and trial. 
 
Figure 1 
Geoffrey Moore (Moore, 2002) begins with the diffusion of innovations theory 
from Everett Rogers, and argues there is a chasm between the early adopters of the 
product (the technology enthusiasts and visionaries) and the early majority (the 
pragmatists). Making the transition between visionaries (early adopters) and pragmatists 
(early majority) is the most difficult step. Moore believes visionaries and pragmatists 
have very different expectations, and he attempts to explore those differences and suggest 
techniques to successfully cross the "chasm". Moore suggests that creating a bandwagon 
effect in which enough momentum builds will facilitate a technology/product becoming a 
de facto standard. However, Moore's theories are only applicable for disruptive or 
discontinuous innovations. Confusion between continuous and discontinuous innovation 
is a leading cause of failure for high tech products. 
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Technology adoption research is a mature field with many different models, such 
as Rogers’s innovation diffusion theory (Rogers, E.M. 1995), theory of planned behavior 
(Ajzen, 1985) and Technology Acceptance Model (TAM) (a review by Venkatesh, 
2007).This adoption process can be related to the scale of innovation efforts by 
distinguishing between macro-level theories and micro-level theories. Macro-level 
theories focus on the institution and systemic change initiatives. Innovation typically 
involves broad aspects of curriculum and instruction and might encompass a wide range 
of technologies and practices. Micro-level theories, on the other hand, focus on the 
individual adopters and a specific innovation or product rather than on large-scale change. 
Technological innovation in healthcare requires expertise in technical considerations and 
clinical practice, changes in organizational dimensions (Cresswell, 2012, Stockdill, S.H, 
1992, and Rogers, E.M. 2008). Therefore, to successfully facilitate technology adoption 
in healthcare must address technical, cognitive, emotional, and contextual concerns. 
2.3 Technology	Acceptance	Model	
Technology Acceptance Model (TAM) is the most influential model, originally 
proposed by Davis FD in his doctoral thesis in 1986 (Davis et al., 1989). Other models 
for technology adoption are quite similar and fine-tuned from TAM. TAM is initially 
meant to explain the user acceptance in computer science. This model is commonly 
employed for describing an individual’s acceptance of information systems (Davis et al., 
1989). TAM assumes that an individual’s information systems acceptance is determined 
by two major variables: Perceived Usefulness (PU) and Perceived Ease of Use (PEOU) 
and the model can be depicted as Davis proposed (Davis, 1989): 
 
 
 
 
The robustness of this model has been demonstrated by different applications to 
different technologies under different situations with different control factors and 
different subjects. A number of extended variables were proposed through the 
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progression of TAM research and summarized in Lee’s extensive review article (Lee et 
al., 2003), which among others include relative advantage or value compatibility, 
complexibility, observability, trialability, visibility and social influence.  
 Relative advantage or value: the degree to which an innovation is perceived as 
better than competing products. 
 Compatibility: the degree to which an innovation is perceived to be consistent 
with the existing values, experience and needs of potential adopters. 
 Complexity: the degree to which an innovation is perceived as being difficult to 
use or understand. 
 Trialability: the degree to which an innovation can be experimented with on a 
limited basis. An innovation that is trialable represents less uncertainty for 
potential adopters, and allows for “learning by doing”. 
 Observability: the degree to which the results of an innovation are visible to 
others. The easier it is for others to see the benefits of an innovation, the more 
likely it is to be adopted. 
With extensive over three decades’ research, TAM has been demonstrated as an 
efficacy theoretical model with good generalizability and predictive validity (Venkatesh 
et al., 2007). One example is its extensive application in phycology and organizational 
behavior (Benbasat and Zmud, 2003, Whinston and Geng, 2004).  
Although TAM has been applied to hospital information adoption previously, 
scarcity exists in empirical studies in research of adoption and implementation of 
innovative technology in healthcare, especially surrounding the organizational issues, 
which is in part due to the lack of “coordinated efforts toward more theoretically-
informed work” (Cresswell, 2012).  
As PCM is partly manifested as a high integrated informatics platform to 
clinicians and biologists, so in this study we will take advantage of TAM for information 
science and organizational behavior research and then extend TAM theory to study the 
organizational issues in technology adoption. This will be done through the analysis of 
users’ PU and PEOU at individual level and identifying successful/limiting factors for 
adoption embedded in the organizational and social dimension. In combination of the 
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notion of “fit” (Ammenwerth et al., 2006), we can further analyze how these factors 
interact with each other, and will emphasize the better fit among technical, social and 
organizational dimensions, the more likely a successful adoption will be assumed.       
2.4 Fit	of	Human,	Organization	and	Technology	Factors	(HOT‐fit)	
A human, organization and technology-fit (HOT-fit) framework was developed 
through a comprehensive literature review and extensive model validation in the field of 
innovation of health information system (HIS) (Berwick, 2003, Yusof et al., 2007). The 
model addresses categories of the HOT factors and interrelated dimensions, and points 
out that a mutual alignment will more likely ensure a successful adoption and 
implementation of an HIS innovation.  
HOT-fit incorporates user’s satisfaction and system use as human elements 
(Yusof et al., 2008). User’s satisfaction is defined as overall evaluation of a user’s 
experience in using the system and is often related as a measure of system success. 
System use is concerned with the frequency and breadth and can be related to the persons 
who use it, their levels of use, training, knowledge, belief, expectation and acceptance or 
resistance (Yusof et al., 2007). Different types of systems can have particular functions 
and users, there may exist various type of resistance, such as people-oriented, system-
oriented and interaction-oriented (Jiang et al., 2000). People-oriented resistance is the 
results from user’s personal characteristics such as age gender, background, value and 
beliefs, which can influence the individual’s altitudes towards to the technology. System-
oriented resistance is related to system design factors or relevant technology including 
user interface and system characteristics. Interaction between people and system can 
result in interaction resistance. 
The very nature of a specific healthcare system can be determined by its structure 
and environment (Cresswell and Sheikh, 2012, Anderson, 1997). Organization structure 
is described as type and size, culture, politic, hierarchy, autonomy, strategy, management 
and communication. The environment of the healthcare organization is consisted of its 
financing source, government, politics, localization, competition, inter-organization 
relationship and population served.      
System quality is central technology element and is often related to the system 
performance and interface. In healthcare setting, measure of system quality includes ease 
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of use, ease of learning, response time, usefulness, availability and security (Yusof et al., 
2008, Anderson et al., 1993). It is important to determine if the system 1) meets the needs 
of the projected users; 2) is convenient and easy to use; 3) fits the work pattern of the 
intended professionals. Information quality is often subjective from user’s perspective 
regarding information completeness, accuracy, legibility, availability and reliability 
(Yusof et al., 2008, Anderson et al., 1993). Service quality is concerned with overall 
service delivered from both internal and external. It can be measured through technical 
support, responsiveness and follow-up service.  
Net benefit captures the balance of positive and negative effects on its users, 
either on individuals or on organizational performance. The individual impact is related 
to the changes in behavior, user task, work activity and productivity. The organizational 
impact is the effect on the organizational performance. In healthcare, clinical outcomes 
are used as measurement of the benefit and can be quantitatively measured through cost 
reduction, improved efficiency in patient care, mobility (the rate of incidence of a disease) 
and mortality (death rate); or qualitatively measured as quality of care, impact on patient 
care and communication. Some barriers to HIS adoption by physicians are identified, 
including low level of IT expertise, lack of acceptance and alteration of traditional 
workflow.   
2.5 Stakeholder	Theory	
The stakeholder theory was proposed in a strategic management book by Freeman 
in 1984. He proposed that a corporation has to create values for all the stakeholders as 
whole, not in separation. The success is made by all the stakeholders together and all 
stakeholders can create values that anyone of them cannot create in isolation.  All 
individuals/entities involved in or influenced by a project can be viewed as a stakeholder 
and they can be internal or external. This theory refocuses decision-making power and 
the benefits of labor from those who invest money (stockholder) to stakeholders broadest 
defined as ‘‘any group or individual who can affect or is affected by the achievement of 
the activities of an organization’’ (Freeman, 1984). For a simplest summarization, 
stakeholder theory studies “The principle of Who and What really counts”(Walsh, 2005, 
Freeman, 1984). Stakeholder can include governmental bodies, political groups, 
communities, financiers, suppliers, employees, and customers and  their status are 
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derived from their capacity to affect the firm and its other morally legitimate stakeholders.      
The nature of stakeholders is richly described in the academic literature (Friedman and 
Miles, 2002). Various ways in identifying stakeholders have emerged such as behavioral, 
ecological, institutional and resource dependence theory  (Post et al., 2012, Freeman, 1984, 
Wood and Jones, 1995). However, none of single attribute within these theories can guide 
us to reliably separate stakeholders from nonstakeholders, and to explain whom and what 
a manager should pay attention to. Mitchell (Mitchell et al., 1997) proposed a theory of 
stakeholder salience and developed a typology, which permits the explicit recognition of 
situational uniqueness and managerial perception to explain how managers prioritize 
stakeholder relationships. In the typology, stakeholders can be identified by their 
possession of attributes among power, legitimacy and urgency. Stakeholder salience-
defined as the degree to which managers give priority to competing stakeholder claims- is 
positively related to the manager perceived cumulative number of stakeholder attributes.         
Power is defined as a relationship among social actors in which one social actor, 
A, can get another social actor, B, to do something that B would not have otherwise done.  
Power in the organizational settings can be characterized based on the type of resources 
used to exercise the power as: coercive power, based on physical resource; utilitarian 
power, based on the material or finance resource; normative power, based on the 
symbolic resource (Etzioni, 1964).Therefor a party with a power in a relationship could 
use these resources to impose its own will in a relationship. The access to those resources 
is not steady, thus the power is transitory as well. 
Legitimacy is loosely referred to socially accepted and expected structures or 
behaviors, often is implicitly coupled with the power for evaluating the nature of 
relationships in society. Suchman (Suchman, 1995) suggested an evaluative, cognitive 
and socially constructed nature of broad-based legitimacy by defining legitimacy as “a 
generalized perception or assumption that the actions of an entity are desirable, proper, or 
appropriate within some socially constructed system of norms, values, beliefs, and 
definitions". This definition implies that legitimacy is a more shared perception within a 
societal system and it may be defined at various level of social organization.  
Urgency is defined in dictionary as “calling for immediate attention” or 
“pressing”. Urgency exists only when two conditions are met: (1) when a relationship or 
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claim is of a time-sensitive nature and (2) when that relationship or claim is important or 
critical to the stakeholder. Based on the time-sensitivity and criticality, urgency is defined 
as degree to which stakeholder claims call for immediate attention. Urgency is perceived 
as the catalyst element for capture of the stakeholder-manage dynamic relationship 
(Mitchell et al., 1997). The concept of paying attention to relationships between 
stakeholders in a timely manner has been the focus of management issues (Wartick and 
Mahon, 1994). Mitchell (1997) has identified 7 classes of stakeholders based on the 
combinational possession of one, two or all three attributes: power, legitimacy and 
urgency, as illustrated in Figure 2. They provide a framework for understanding how a 
stakeholder can gain or lose salience to a firm’s managers and lay ground for analysis of 
dynamic nature of stakeholder-manager relationships. 
 
 
Figure 2. 
The salience of a particular stakeholder to the firm's management is low if only 
one attribute is present; moderate if two attributes are present; and high if all three 
attributes are present. Stakeholders can change in salience, by requiring different degrees 
and types of attention depending on their attributed possession of power, legitimacy, 
and/or urgency, and levels of these attributes, thereby salience can vary from issue to 
issue and from time to time. This model added dynamism to the static maps of a firm’s 
stakeholder environment enabling a more systematic sorting of stakeholder-manager 
relationships as these relationships attain and relinquish salience in the dynamics of 
ongoing business. In addition, model permits managers to map the legitimacy of 
stakeholders and therefore to become sensitized to the moral implications of their actions 
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with respect to each stakeholder. Thus, these refinements contribute to the potential 
effectiveness of managers as they deal with multiple stakeholder interests.  
By employing agency theory, Hill and Jones (Hill and Jones, 1992) have 
developed a stakeholder-agency theory and proposed that managers have the 
responsibility to reconcile divergent interests by making strategic decisions and allocating 
strategic resources in a manner that is most consistent with the claims of the other 
stakeholder groups. This model was based on the fact that the managers have a unique 
position at the center of the nexus of contracts, namely they are the only group of 
stakeholders who enter into contractual relationships with all other stakeholders and who 
also directly control over the decision-making apparatus of the firm (Hill and Jones, 
1992). Therefor the characteristics of managers are vital for a manager to identify the 
stakeholders, to decide which stakeholder is salient to the firm and which stakeholders 
should receive management attention. Stakeholder salience is positively related to the 
manager perceived cumulative number of stakeholder attributes. 
2.6 Development	of	Propositions	
Drawing on the theoretical foundation presented here, we realize that healthcare is 
an adaptive system and technology adoption in healthcare intersects with a broad 
embedded context (technology, human and organizational context), which together will 
determine multi-faceted nature of the actual process of technology adoption in a specific 
healthcare system. We propose propositions: 
Proposition1: New technology adoption in healthcare is in response to an 
exogenous and endogenous stimulus and actions. The entrepreneurial-oriented scientists 
perceive the opportunity and proactively promote the technology adoption. The user 
perceived usefulness of this technology for resolving an important societal problem stays 
centrally for the possibility of adoption.  
Proposition2: The characteristics of the technology and nature of the problem 
being addressed will determine the pattern of adoption through a manner of intersecting 
with a specific adoption system and the broad context.  
Proposition3: The technology champion advocating an innovative technology is 
at the center nexus of early technology adoption in the Norwegian healthcare. 
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Proposition4: The alignment of stakeholders’ perceived benefit in a broad context 
will influence the trajectory of technology adoption.  
2.7 Summary	of	the	Theoretical	Framework	
Based on the propositions, the framework of the study can be summarized as 
following: 
The dependent variable for measuring PCM technology adoption is the actual 
use of the technology in the Norwegian healthcare system.  
The independent variables are the factors which have influence in the process of 
technology adoption and defined in the theoretical grounding part, including the nature of 
the problem being addressed, characteristics of healthcare, finance, human, technology, 
organizational, ethic perspectives and broad context such as government policy and 
national strategy. 
The control variables are all national influential factors, which are thought to 
have a direct impact on technology adoption in Norwegian healthcare in general. Since 
the purpose of this study is to understand how this particular technology is adopted in 
Norwegian healthcare, factors which might have a direct impact on technology adoption 
in Norwegian healthcare in general are controlled for. These include general funding 
other than the funding specifically to this project, scientific environment, R&D level and 
expenditure in the country, healthcare policy reforming, etc. Such factors do have an 
impact on technology adoption in general. The theoretical framework is presented in 
Figure 3. 
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Figure 3. 
3. Methodology	
3.1 Research	Design	
3.1.1 Research	Paradigm		
The interpretivism is taken as the main research paradigm in this study. This 
physiological basis is popularly used in ethnography and other social science.      
Interpretivists believe that the reality is relative and multiple. These multiple meanings 
are very difficult to interpret as they depend on other systems and context. The 
knowledge generated from this discipline is perceived through socially constructed and 
subjective interpretations (Carson et al., 2001, Hudson and Ozanne, 1988). Interpretative 
study is not reporting “facts”, but based on “thick description” to make interpretations of 
other people’s interpretations. Interpretative study is not aiming at producing “truth”, but 
still generalizable findings. This research paradigm is used in three ways in this study: 1) 
as an initial guide to design and data collection-build on the previous knowledge; 2) as 
part of an iterative process of data collection and analysis-initial theories being expanded, 
revises or abandoned; 3) as a final product of the research. Interview is the main source 
of data for this type of research. The investigator tries to be objective and unbiased. The 
researcher’s rich prior experience and knowledge in biomedicine/biotechnology is 
valuable for gaining an in-depth interpretation during the study.  
The positivism philosophy is also applied in the study pertaining to evaluation of 
the technological issues and identification of the successful factors and barriers in the 
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progression of the technology adoption.  The positivist believes there is a single, external 
and objective reality to the research question regardless of the researcher’s belief (Carson 
et al. 2001, Hudson and Ozanne 1988), therefor researchers are detached observers and 
they make generalization and abstraction by using rational and logical approach through 
obtaining hard secure objective knowledge.   
3.1.2 Research	Method	
Qualitative research method is appropriate when one is trying to answer “how” 
and “why” questions in-depth (Yin, 2008). This is a study about a contemporary, on-
going project in its real-life context and is designed as an descriptive and exploratory 
single qualitative case study, where we provide an understanding of the situation as 
complete as possible through in-depth longitudinal description of the circumstances under 
evaluation, the characteristics of the people involved in it, the nature of the community 
and cultural norms/values in which it is embedded. With this holistic understanding, the 
interplay of the variables is examined. This study intends to use a combination of 
deductive and inductive logic to answer the question how an innovative technology can 
be adopted by Norwegian healthcare system.  
An embedded-case study containing several analysis sub-units is planned by 
analyzing the qualitative data collected from documents, meetings and semi-structured 
in-depth interviews with executives from all stakeholder organizations. The analysis sub-
units include individuals, organizations and inter-organizations. Relevant variables 
defined in the literature review part will be analyzed at individual level, organization 
level and inter-organization level. In this manner, we gain deep understanding how the 
whole Norwegian healthcare system is prepared for adoption and diffusion of this 
innovative technology, how the innovation are reinvented to match Norwegian healthcare 
system in practice; and we identify some missing links inside or inter-organizations for a 
more efficient adoption. This in-depth study may provide information basis about the 
ongoing activities for managers and decision-makers to identify both present and missing 
success factors for further managerial actions. Case study protocol and case study 
database are included in the appendix. 
Through a literature review, the initial framework is formulated. This framework 
provides guidelines for the choice of research method, designing research protocol and 
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data analyzing. The framework is revised and validated based on the existing theory and 
results from the case study. This iterative research design is illustrated in the following 
figure 4. 
 
Figure 4. 
3.2 Selection	of	Participants	and	Data	Collection	
All the key entities involving in the adoption of PCM as listed in the table 1 are 
the analysis units and thus participants in the study. The key executives or managers of 
these entities are the informants initially recruited in the interviews. The snowball 
technique was used for recruiting additional relevant informants. A total number of elven 
key executives representing all stakeholders in the case are selected for interviews. We 
gained generally good access to the informants with some difficulty to only one 
organization. This may indirectly reflect the degree of stakeholder involvement in the 
current stage of technology adoption- the higher involvement, the easier access. In 
addition to conducting interviews, primary data is also collected through attending 
meetings/debates and correspondence with a focus group representing clinicians, patients 
and managers in hospital and governmental regulatory agency. In the situation where 
there is no interviewee available in the entity, we attended meetings for gaining the 
primary data. This sampling regime allows us to gather in-depth contextual information 
both inside- and inter-organization about the progress of technology adoption. This 
triangular information will build up multiple chain of evidence towards the fact, which 
will reduce bias and enhance the validity and reliability of the evidence.   
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By employing semi-structured interview method, we are open to all-round 
perspectives from all the stakeholders, while staying focused on the topic. Interpretivist 
investigator enters the field with some sort of prior insight about the research topic but 
assumes that this is insufficient in developing a fixed research design due to complex, 
multiple and unpredictable nature of what is perceived as reality. During the data 
collection stage, the investigator and the informants are interdependent and mutually 
interactive with each other and construct a collaborative account of perceived reality. The 
investigator remains open to new ideas throughout the study and let it develop with the 
help of his informants. The use of such an emergent approach is also consistent with the 
interpretivist belief of human’s ability to adapt and no one can gain prior knowledge of 
time and context bound social realities (Hudson and Ozanne 1988). These interviews 
server as our primary data source for analysis, from which we have possibility to obtain 
both holistic and detailed organization-, process- and event-based information about the 
project.  
Before interview, our interviewees are well informed about the purpose of this 
study and the questions we shall focus on. A good rapport was generally established 
between investigator and informants beforehand. The informants talked about topics 
related to PCM adoption, how they perceive the value of the technology, milestones and 
challenges pertaining to their roles in the project. The interviewees were interviewed for 
about one to two hours. The interview was audio-recorded with permission from 
interviewees for further analysis, while investigator is taking note. Anonymity is ensured. 
The interview questions are listed in the Appendix. 
Some informants are unfortunately not available for a personal interview. The 
specific information related to PCM was collected through attending meetings and email 
correspondence. Overview of primary data collection was set up as Table 1. The number 
of informants includes the total number where the primary data was collected both from 
PCM meeting and interviews. Some interviewees have several positions in different 
organizations.    
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Table 1. 
Secondary data is gathered from archival records, academic journals, scientific 
meetings, strategy documents, annual reports, government reports, meeting memoranda, 
survey data and various websites (association, pharma and technology companies), which 
can be used as information for cross check and conformation during analysis.  
All the information from multiple sources was used to corroborate each other. 
Case study protocol and case study database are shown in appendix. 
3.3 Data	Analysis	
The data analysis strategy was designed in accordance with the research question, 
review of the literature, and propositions proposed in this study. Qualitative data from 
interviews will normally generate large set of data. The redundant data was firstly 
reduced and primary pattern match and time series analysis techniques were used for data 
analysis.  
Pattern matching analysis. Each interview will be firstly transcribed verbatim. 
Each transcript will be read several times in order to ensure a thorough understanding of 
the content. The transcripts were initially open-coded based on the independent variables 
proposed as in the literature review. After an open-coding analysis, the coded information 
is related and cross-linked to each other, which resulted in a hierarchical cluster coding 
structure based on the research boundaries predefined as in the literature review. After 
coding and systematization of the information, the categorized codes appearing in our 
predefined boundaries are taking into further analysis; the categories appearing most 
frequently in the transcripts, however not falling into our predefined boundaries, serve as 
keywords in another round of literature research for identifying their relevance to the 
project. The analysis sub-units include individuals (scientist, physician, project manager, 
policymaker and patient), organizations (governmental agency, hospital, pharm industry 
Organization Number of Informants Position of Informants Focus Group with Interviews
Nasjonalsatsingsgroup (NSG) 3 Group member and coordinaor 3
Norwegian Cancer Society 1 Department leader 1
Norwegian Biotechnology Advisory Board 1 Senior Secratory 1
Oslo Cancer Cluster 2 Senior Advisor 1
Norwegian Medical Association 1 Excecutive
Cancer registration 1 Head 1
Radium Hospital 5 Oncologist, Parthologist, Biologist & Excecutives 5
Industry Partner 2 Excecutive 1
Sum 17 11
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and) and inter-organizations (communication and collaboration). Relevant variables 
defined in the literature review part will be analyzed at individual level, organization 
level and inter-organization level for stakeholders.   
A time series analysis has been conducted to reveal how critical event driving the 
process forward and how important factors from the pattern matching technique evolve in 
time. This analysis allows us to trace the changes over time through following the course 
of events in order to reflect the research question and the theoretical groundings. This 
analysis can also increase the validity (Yin, 2008). 
3.4 Validity	and	Reliability	
When participating in your own research, the researcher could be subconsciously 
subjective. Therefor from a case study perspective, it is important to establish a 
plan/tactic for ensuring validity and reliability of the research (Yin, 2008). Based upon 
the framework defined by Yin regarding to ensuring validity and reliability, the following 
actions during each phase of this study were taken in order to ensure better validity and 
reliability: 
 Phase of research design: The interviews were designed under the consideration 
of both internal (content) and external (construct) validity. All the interviews 
begin and end with the same questions. A design of 360 degree interviewee 
around the case provides multiple sources of evidence and serves as a good basis 
for validity and reliability. The use of focus group provides a possibility for an 
additional clarification on the question as needed. The supervisor has reviewed 
research design and a case study protocol is established. 
 Phase of data collection: The same interview procedure is followed for all the 
interviews and same questions were asked to different interviewees/stakeholders 
when it is fitting. The answers were compared to each other and to documents. If 
the answers are not within the same line, the additional information is sought for 
further analysis and confirmation. Therefore, multiple sources of evidence and 
chain of evidence are established.  
 Phase of data analysis: Interview recorders and transcripts were listen/read 
through several times to ensure a complete understanding of the content. A 
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database containing clean primary data was created for an easy use of complete 
data. Some analysis method such as patterns matching, explanation building and 
time series analysis will enhance the internal validity. The patterns were identified 
through above mentioned analysis.  
 Phase of composition: The key informants and supervisor have reviewed the 
manuscripts to ensure better construct validity. This triangulation of evidence can 
enhance the validity and reliability.  
4. Results		
The findings based on the primary and secondary data are presented with a 
structure of time-series analysis. We have divided the process of PCM adoption into three 
stages: decision-making, technology acquisition/development, and rollout to cross the 
chasm. In each stage, the main events and critical factors based on the theoretic 
groundings are described and narratively analyzed. This analysis allows us to trace the 
changes over time for the purpose of reflecting the research question and the theoretical 
groundings. Each of the following sections describes the findings related to each phase of 
technology adoption and a general pattern is matched to the theories based on the analysis 
according to the theoretical framework presented in Figure 3.  
4.1 Decision‐making	for	PCM	Technology	Adoption	
Personalized medicine (PM) represents the trend for more précised personal 
medical care. This section describes how PCM adoption is discovered as an opportunity 
and set as a national priority to be exploited under the stimulation of both exogenous and 
endogenous factors. 
4.1.1 The	Initiative	from	Entrepreneur‐Oriented	Researchers	
The earliest national initiative for PCM was made by a five-person group in 2011. 
The group consisting scientists and clinicians from the four health regions of Norway 
submitted a proposal to the health department, suggesting “National priority cancer: 
Individualized cancer treatment for all Norwegian patients based on the gene profile of 
their own tumor” (Roy Bremnes, et al 2011). In this proposal, a strategy for building up a 
national coordinated research and translational platform to provide a targeted cancer 
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treatment using molecular tumor diagnosis is proposed. This proposal was given priority 
by the Norwegian Research Council (NRC). The leader of this writing group is leading 
the “Nasjonalsatsgruppe (NSG) for kreft” responsible for the strategic planning and 
professional advising, at same time creating a framework for all the stakeholders. In 
response to this proposal, NRC set out a financial scheme and called for proposals for 
PCM. A PCM project was granted in 2012 to the national collaboration group for health 
research-Norwegian Cancer Genomics Consortium (NCGC), and a leader from NCGC 
was assigned for the PCM program. The NSG group members were included as key 
investigators for the PCM technology adoption and the practical implementation of the 
strategy. 
The members of this writing group have strong background not only in basic 
research and clinic, but also in translational research, innovation and technology. Some of 
them held several patents and were in the process of commercialization of their 
technologies. These experiences made them particularly aware of the novel technology in 
industry and market. According to the writing group, “The rationale behind the first 
initiative is two-fold. Firstly, the knowledge accumulated about the mutations in 
tumorgenesis and drugs specifically targeting those mutations. There are good cases 
where a drug works for different cancers and the same mutation involved. Various kinds 
of sequencing technologies have been improved and a more feasible price is gradually 
achieved for clinical use. The technology has been used in many prestigious hospital and 
institutions across the world. We cannot simply wait for its automatic happening in 
Norway. We have to take actions to make it happen, otherwise it will never happen. 
Secondly, we have a group of scientists whose scientific level is recognized at high 
international level. We have a good healthcare system to follow every cancer patient from 
diagnosis to the whole treatment. We have collected a large size of samples, for example 
in lymphoma. How should we organize these resources and expertise to deliver a better 
healthcare and to lift our research level? Focusing on the molecular level for cancer 
patient care is one field that we have particular strength and resources, and thus a 
promising way to develop. Although from the historical data we have not yet seen a 
magic bullet yet for cancer treatment, whether PCM might be the magic bullet, we have 
to try out. We are always looking for new technology.” 
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These visionary researchers envisioned PCM as a great opportunity for improving 
the Norwegian healthcare service. They took initiatives to gather expertise, lobby 
politicians for financial support. Their actions successfully strengthened the concept of 
PCM from the national top management. This proposal was systematically evaluated by 
Health technology assessment (HTA) in terms of resource use, the application of  the 
technology, and a set of technology- related issues including ethics. It is clear that PM 
will gradually be incorporated into cancer patient management and will have a significant 
impact on our health care in the future (Diamandis et al., 2010). In compliance to the 
Norwegian framework, PCM was set as a major movement towards a better personalized 
cancer care in national strategy and a top-down approach to PCM adoption is initiated.  
These scientists proactively take part in the establishment a national platform for a 
more personalized cancer treatment at an accurate molecular level based on patient’s 
genomic information. The suite of clinical applications of PCM in cancer is broad, 
“encompassing screening, diagnosis, prognosis, prediction of treatment efficacy, patient 
follow-up after surgery for early detection of recurrence, and the stratification of patients 
into cancer subgroup categories, allowing for individualized therapy. By dividing patients 
into unique cancer subgroups, treatment and follow-up can be tailored for each individual 
according to disease aggressiveness and the ability to respond to a certain treatment”, said 
an executive in the interview, “This is an advanced technology. To achieve the goal, we 
need to establish a national platform where the new service can be developed by 
leveraging our best expertise in academy, clinic and industry.”    
4.1.2 Governmental	Support	
Cancer research is set as one of the prioritized field and the patient is the focus. 
There have been some public funds invested into this priority, including the ones from 
NRC, Cancer Association and the regional health departments. In 2008, the Oslo Cancer 
Cluster proposed a concrete solution to a temporary funding for promising cancer 
treatment-“innovasjonsfond”. In early 2012, the NRC launched a new large-scale 
initiative for biotechnology: Biotechnology for innovation (BIOTEK2021). The 
estimated budget for the entire program period (2012-2021) is approximately NOK 1.4 
billion and the budget for 2012 is approximately NOK 140 million. BIOTEK2021 aims to 
promote biotechnology researches by funding large-scale, long-term projects that address 
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wide-ranging societal challenges. This program evolves from the previous national 
FUGE program, which has invested in NOK 1.6 million over ten years with benefit to a 
broader-based initiative and played an important role in the creation of new Norwegian 
companies. Activities under FUGE platform will be followed up and expanded under the 
new BIOTEK2021 program.  
BIOTEK2021 identifies “biotechnology is at the very core of the bioeconomy and 
a key element in the development of the agricultural, marine, industrial and health sectors” 
for generating new and improved products, services and processes which contribute to 
the emerging knowledge-based bioeconomy. A key objective of developing Norway’s 
fledgling bioeconomy is to maximize sustainable production and processing of renewable 
biomass for a variety of products.The strategy provides a framework for research 
initiatives in the interface between social challenges, national competitive advantages and 
opportunities inherent in biotechnology activities. The complexity and dynamics of the 
interaction between research, technology and society are increasing rapidly, giving rise to 
needs for greater knowledge and reflection about the changes we are facing. The 
BIOTEK2021 program will generate research-based knowledge by applying 
biotechnology as a basis of understanding life processes, developing policy and 
generating innovation and industrial development to help to solve major social challenges.   
PCM adoption has been funded by a substantial grant from the NRC, under the 
Program for “publicly initiated clinical cancer studies” and BIOTEK 2021 program for 
“A national research and innovation platform for personalized cancer medicine” towards 
2017.  
4.1.3 The	Norwegian	Approach	to	the	PCM	Adoption	in	Practice		
In response to the national strategies including “BIOTEK2021”, scientists have 
proposed to establish a national platform for personalized cancer medicine by utilizing 
the core competence in the translational cancer research from both academy and industry. 
With the funding from research council, the PCM program focuses on better utilization of 
existing research capacity and results, at the same time takes into account the 
commercialization of medical products and services. The main mission of this program is 
two-fold: 1) to analyze molecular characterization of the patient’s tumor, thereby 
ensuring the patient receives targeted treatment with better outcome and less side-effect; 
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2) to capture the clinical and genetic data to form a cohort dataset of genetic changes, 
treatments and outcomes for research and industry. Taking advantage of the knowledge 
and technology advances, it is possible to make molecular diagnosis as an effective 
personalized cancer treatment. However, clinical use of PCM is at its infancy with 
discrepancy from different clinical settings and there is no established ready model that 
Norwegian healthcare could copy from. Therefore, demonstrating a workable model for 
delivery of a quality assured effective cancer treatment compliant to Norwegian 
conditions is a strong motivation for the program. 
This PCM program sets out the framework with strong collaboration between 
universities, hospital research institutions and industry partners. The program is led from 
the Oslo University Hospital (OUS) and coordinated with the Oslo Cancer Cluster. 
Principle investigators and clinicians, industry companies have formed a partnership 
within the program. All the stakeholders and their roles in the program are summarized in 
the following table 2: 
Organization Role in PCM adoption 
Health department Policy making and monitoring  
Nasjonalsatsgroup (NSG) 
Strategy and professional advising for PCM, 
 create a national network 
Bionemmda 
Evaluate social and ethical consequences of biotechnology, 
give advice to government 
Kreftforeningen 
Raise funding for research and technology implementation, 
communicate with public 
Research Council 
National strategic and funding agency for research & 
implementation of technology, give advice on research 
policy for the government 
Oslo Cancer Cluster Facilitate cancer research and clinical use of technology 
Legeforeningen Provide better public health service, health political actor 
Cancer Registry Population-based clinical cancer registration 
Biobank Collection and storage of patient’s tumor sample 
Hospitals 
Technology hub for better research and clinical use of 
technology  
Pubgene  Develop highly integrated informatics platform 
Pharm industry partner Commercialize product and drug discovery  
Table 2. 
Currently, PCM has been adopted in four national health regions with established 
sequencing technology platform in OUS/UiO, UiB, NTNU and UiT. Clinical sequence 
data has been collected through the pilot clinical trials by collaborations between the 
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clinicians and scientists in the regional sequencing platform. This data will transfer the 
specific findings for the routine molecular pathology test and to inform clinical decision-
making. The genetic data will be registered in the cancer registry and compose a national 
mutation database for further cancer biology research and drug discovery. Through this 
process, some main achievable objectives are set:“ 1) to investigate the mutations of 
known actionable genes across several important cancer types using existing biobanks; 2) 
to establish sampling procedures and sample logistics, bioinformatics infrastructure, 
analysis and pipelines, as well as procedures for feedback to the treating centers and the 
Cancer Registry; 3) to initiate clinical prospective studies based on biological hypotheses 
including two or more participating centers;  4) the implementation of phase 1 and 2 
studies based on the initial findings and current know-how; and 5) educational efforts 
towards the health service and patients”, according to the program leader. 
In practice, the program will sequence 1000 patients in various small clinical 
trials across the nine cancer types within the first three years. These cancer types are 
chosen because the higher incidence rates wereobserved for the Norwegian 
populationand there has been a strong research effort within these cancer types in the 
country. DNA extraction and analysis will be conducted at the technology platforms in 
those four universities. Surplus biopsy material will be sent to biobank appropriating 
further research. Lager series of common cancers and longitudinal studies of few patients 
(N=1 trial) will be conducted and the outcome data of the personalized treatments and 
other therapies stratified by mutation profiles will be accumulated over time. The data 
will inform clinicians with diagnosis, treatment and prognosis. At the same time the 
information gathered will be valuable for both academy and industry R&D activities. An 
integrated informatics solution will be developed for capture, storage, access and analysis 
of the clinical and genetic data.  The process can be described by the following flowchart: 
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After approval of the concept, this model will integrate the lessons learnt from the 
adoption into a more mature model for reaching the long term goal: implementing in 
clinics for providing a standardized, cost-effective and routine practice for the cancer 
treatment in Norwegian healthcare, at the same time lifting the level of Norwegian cancer 
research using the enriched national mutation database.    
With influx of the public fund, a series of milestones were achieved accordingly 
and they collectively drove the process of PCM adoption. Through a time-line analysis, 
the major milestones are identified with some possible overlapping in Figure 5. The 
whole process is delineated into three stages: decision-making, technology 
acquisition/development and roll out.    
 
Figure 5. 
In this process, a well-articulated solution addressing a public health problem was 
proposed by visionary scientists and set as national priority for implementation. 
Government agencies have been important factors in making  policies and allocating 
public funds to facilitate the technology adoption. Tight collaborations between 
universities, hospital and industry are central for integrating national expertise and 
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resources to provide this innovative technology for cancer patient. Overall our data 
supports the proposition: 
Proposition1: New technology adoption in Norwegian healthcare is in response 
to exogenous and endogenous stimulus. The entrepreneurial-oriented researchers 
perceive the opportunity and proactively initiated the technology adoption. The user 
perceived usefulness of this technology for resolving an important societal problem stays 
centrally for the possibility of adoption. 
4.2 The	PCM	Technology	Acquisition/Development	in	Norwegian	
Healthcare		
Since the PCM adoption is set as the national priority, a top-down program-based 
strategy is applied for establishing a national platform as an actual form of technology 
adoption. PCM adoption encompasses not just a new service, but also clinical, 
organizational, regulatory, financial and relational changes involving multiple 
stakeholders. In this section, we delineate how the critical elements - technology, human 
and organization within the Norwegian healthcare system, interact or are aligned together, 
and how they collectively influence PCM technology acquisition and development.  
4.2.1 Technology	
In the PCM technology adoption, it involves adoption of two different 
technologies, namely sequencing technology in the lab and an integrated informatics 
system for data capturing, analysis and interpretation. With the funding scheme from 
NRC and “BIOTEK 2021”, there was no grant for purchasing machines. An additional 
grant from “Radiumhospital Legacies” was received for purchase purposes. Currently, a 
sequencing platform infrastructure is established at the Radium hospital and the machine 
is running at its maximum capacity. Several clinical trials have been initiated across 
hospitals.   
The technology is chosen according to government guidance combined with local 
system conditions, it is thus more likely to satisfy the users and organizational needs. The 
current employed sequencing technology at the Institute for Cancer Research at the 
Radium hospital, is Hiseq2500 - the newest innovation from Ilumina. The Ilumina 
technology has been used in the institute as part of the previous FUGE national platform. 
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FUGE platform during past 10 years has built up the necessary capacity and competence 
in DNA sequencing and data analyzing by using Ilumina sequencing technology and data 
capturing system. “Now with the newest Ilumina sequencing machine, we are able to 
work at higher efficiency, accuracy and lower cost. Now running a whole genome exon 
sequencing for one patient including a pair of tumor and a normal tissue sample takes 25 
hours and costs around 18,000 NOK, which is already quite good”, according to an 
executive. “With the newly established robot assistance, the sequencing efficiency can be 
further increased. Technology advances dramatically and a relatively high standard 
technology is important for its long term development. The industry is under constant 
development for the better technology. We expect it becomes a more economy-friendly 
technology, especially in the routine use for following-up the patients during the 
treatment regime.  The more patient we include in the trial and the more data collected, 
the more powerful the technology becomes.” 
Currently there are two different technology systems employed nationally within 
the PCM project. The Ilumina technology is chosen in Oslo, Trondheim and Tromsø, 
while Bergen is using another technology. The different technology represents different 
detection precision and different sample preparation procedure. Presently, sequence data 
has been compared and validated across regions with the same technology platform. A 
standardized procedure for sample preparation and data acquisition will be applied at 
these regions. However, the data validation between the technologies is not easy due to 
the different nature of technologies. The issues related to data validation as well as an 
applicable standardized sequencing protocol across these two technologies warrant 
further investigation for establishing a PCM national platform. 
When it comes to using IT system, each healthcare provider has his/her own 
agenda. In relation to PCM, the IT usage is a medical/medicine related technology and 
Clinicians, Oncologist, Pathologist (COP), biologist are the users. Their initial intensions 
to use this technology are low. These users do not generally possess high IT expertise and 
often have established their own general knowledge and routines pertaining to the patient 
diagnosis and treatment. “I have been doing diagnosis in the traditional way for my 
whole career and it works fine. And now I have problems to listen to an algorithm for 
diagnosis”, according to a pathologist. In addition to the user intension, the users’ 
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satisfactions are also limited. As stated by a researcher, “the data generated from one 
whole genome sequencing is at level of GB. To fully analyze such a dataset will take 
several months’ work for a skilled bioinformatician with a powerful computing machine. 
Right now, there is no ready, simple software for this analysis. If I opt to analyze this data, 
I need to learn UNIX and get familiar with all the analysis procedure, starting from data 
validation and data mining. That is just too much work before one can get some 
biologically meaningful information out.” For medical professionals, they are much less 
used to such data mining work, and much more rely on their own knowledge and 
experiences for diagnosis and treatment. They do not have time to learn complicated IT 
software.  This IT system is hard to learn to use due to lack of a well-developed 
integrated software and limited technique support.  
Regarding to the system quality, this IT system has low compatibility with 
existing IT system in the healthcare. As a manager said, “We do not have money to 
establish a secure server with sufficient computing capability, so we are renting 
computing capacity from USIT where we also get service from. The system is not a part 
of hospital network and has low compatibility with hospital network. But this is currently 
the most practical setup for getting it up running, even though the data transferring speed 
is not optimal. We can even send data there quicker by taxi.”  Some researchers carry 
their dataset around with a two-kilo hard drives and have to buy a new portable PC solely 
for the data mining process. Users prefer one single IT solution which covers data 
identification, interoperation, integration and integrity. “It is too complicated, as it is 
now.” said a user. “This solution should be more user-friendly with a simple interface for 
data capturing, analyzing and file administration in the clinical settings. For now, the data 
is stored and analyzed at the University’s net, which is separated from the system where 
the patients’ electronic medical records (EMR) are kept. Integration of the PCM data with 
existing EMR is demanded for timely informing doctor’s decision-making. In addition, 
there is no mechanism for user support concerning PCM data analysis and interpretation. 
The data analysis is performed at a basis of group collaboration within the hospitals.” 
There is a need for the development of a better IT solution including a mechanism of user 
support. In this desired solution, a data warehouse containing timely, accurate, valid and 
complete data need to be established. Governance of this data across the organization to 
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ensure efficient resource utilization remains a challenge afterwards. Better user 
involvement will be helpful to fulfill user needs. 
Overall, although the PCM is a complex technology, the technology platform is 
chosen to be established at an institution where long prior experience and favoring 
culture for sequencing technology are in place. Therefor the initial sequencing 
infrastructure was established and up running rather quickly. Contrary to the sequencing 
platform, a good IT solution for data analysis and interpretation has not yet well 
developed. The development and adoption of own IT solution appears much slower. A 
technology specialist as a champion can promote adoption through introducing and 
developing a technology/product fitting well into users' needs thereby enhancing user's 
satisfaction. The data above collectively suggested a proposition:     
Proposition2: The characteristics of the technology and nature of the problem 
being addressed will determine the pattern of adoption through a manner of intersecting 
with a specific adoption system and the broad context.  
4.2.2 Human	
PCM is a technology applied to the Norwegian specialist healthcare. According to 
the work flowchart, the people who will be involved in developing and using the 
technology include mainly clinicians, oncologists, pathologists and biologists. These 
groups of people are represented in the management team of the PCM program. They are 
working externally with the government and industry and internally with management of 
the program. 
These leaders work in different institutes as champions advocating PCM 
technology and are at the center nexus of early technology adoption in various ways. The 
management team consists of key investigators working in key areas ranging from cancer 
treatment, cancer research, sequencing technology to development of informatics solution. 
This profile of management team covers the multi-disciplined fields for development and 
adoption of PCM. They are either leaders in their working institutions or prestigious 
scholars in their own fields. They have together as a team envisioned the huge potential 
and its societal value and streamlined this important massage to politicians. Through a 
close dialog these leaders influenced public policy and secured financing for PCM. This 
money had been allocated to the technology platform and to the expertise within the field 
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by the managers of the program. Thus all the resources (finance, human and technology) 
are well aligned in the same framework. The managers formulated the strategy, dissected 
it into achievable goals and acted as boundary spanners for practical implementation. All 
the members in the program work interconnectedly to collectively arrange resources to 
produce a new service. During this dynamic process, a balanced relationship was 
achieved through decision making for prioritizing various activities and allocation of 
finance. 
The users of PCM technology mainly consist of three groups of people: clinicians 
(oncologist/pathologist), researchers (biologist/bioinformaticians) and cancer patient. 
They value and accept the technology in various ways at different levels according to 
their stakeholders’ role in the technology adoption. Biologists/bioinformaticians possess 
the core competence for integrating findings from basic research, translational research 
and drug discovery to deliver an evidence-based solution for clinical use. They have 
longer experience and thorough understanding about the sequencing technology. They 
perceive this technology as a powerful tool to understand molecular heterogeneity of 
tumors and to develop a more precise approach for cancer treatment. “I regard it as a 
paradigm shift. We need to develop this technology and deliver it to our patient. I hope it 
could be available in my life,” as some researcher mentioned. They are in close contact 
with other group of users, not only to enlighten the theoretical and practical use of PCM, 
but also to incorporate the different users’ needs and make a better system for Norwegian 
patients.  
Patient interacts with this technology in three ways:as the provider of health-
related information; as the receiver of information regarding his/her healthcare condition 
and the treatment; as the recipient of health-related services and care that utilizes the 
information stored in the platform. “According to Norwegian law, patients receive good 
information about their medical conditions by both verbal and paper communication. 
Normally, there is a good trust and communication between clinician and patients. We 
have no problem with the information flow from both sides. Namely, patients collaborate 
well with clinicians, sign the “patient consent” and provide information to doctors 
without problem”, mentioned by both doctors and researchers. “They often accept the 
new technology for the medication and are willing to participate in the trials for treatment 
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recommended to be worth trying. So far, oncologists have started some small clinical 
trials and they have not encountered problems regarding to collect patients’ sample for 
DNA sequencing. When it comes to the national implementation of PCM, I do not 
perceive a problem from the patient side, as long as PCM is proven to be effective like 
previous innovation.” This was confirmed by a cancer patient, that “We are often under 
much stress and have been trying all the different available treatments. In another word, 
we are in a desperate situation. If a doctor recommends a technology/treatment with 
better efficiency and less side-effect, we have no reasons to ignore it and would rather 
give it a try. As far as my DNA sequence data, I do not care so much about it. This is me, 
I am a simple person. But I think there should be a good law rapping up the whole issue.” 
It seems that even though the patients do not possess good knowledge about the new 
technology, they do have a favoring altitude to the PCM adoption and will participate in 
the development of this technology under the consultation of their clinicians.  
Clinicians are the keys bridging the PCM idea to a practical use. “Clinicians and 
researchers are in two different worlds. We (clinician) see patients, but they (researchers) 
do not. I have to pin point one thing is that many researchers emphasize the value of the 
personalized medical care, but the medical care has been always personalized. We make 
all the treatments personalized for each unique patient. As a clinician, I definitely favor 
PCM as it allows a medical care personalized to a more accurate molecular level, instead 
of an individual level. But I firstly have to see more evidence showing that is working. 
Now I understand that PCM is a complicated technology and might be powerful. I do not 
know much about genes. I need more information,” said a clinician and an executive in 
the interview. This statement clearly demonstrates that clinicians are not yet convinced 
with the usefulness of the PCM over the existing technology. They need more evidence 
to prove the actual relative advantage of PCM. “We are always looking for new 
technology. We have a good environment here in the Radium hospital with best expertise 
in the country and we actively communicate with each other. The only problem is that 
clinicians and researcher are with different educations and speak two different languages. 
This diversity is good to create something new, but it is also dividing people into groups. 
How to bring them together is a challenge. We must find out a good selling point to 
clinicians and pathologists. But as long as they receive right information, they will take 
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new technology as a good tool supplementing the existing ones, as seen from previous 
experience.”   
The different groups of people share different perceived usefulness of the PCM, 
which decides their different altitudes about whether they should start use the technology, 
at what time point and how to use it. These decisions collectively shape the pathway of 
technology adoption at the organizational level. For researchers, they are excited about 
the progress and willing to apply the technology in their research. However, the scope of 
technology application in research is limited by the limited data accumulated in the PCM 
platform. The more data collected, the more powerful the tool is, and the higher research 
level can be reached. So researchers are the main driving forces for the technology 
adoption. They have the power of knowledge, infrastructures and money to reinforce the 
development of PCM. They can assure that a reliable, high-quality tool is going to be 
developed, which is a premise for the PCM adoption. Together, researchers as a 
stakeholder in PCM adoption have high power, legitimacy and urgency. 
Clinicians are busy with patients and they work simultaneously with various 
choices for cancer treatment. Although they have motivations to look for “a precise, 
patient-tailored treatment through which the wrong treatment can be avoided and less 
side-effect can be achieved”, they consider the “current cancer treatment is good for 
controlling tumor progression, as most cancer types are indeed curable except some big 
ones. However, the bigger problem is the side-effects associated with the treatment and 
many patients are dead of that. This is especially the problem for young patients, as they 
have not really experienced the world.” This shows that the oncologists have some 
motivations to adopt PCM, but they perceive this not to be anurgent matter. Therefore 
clinician as a stakeholder in PCM adoption has some power, legitimacy and urgency.   
Patients are  loyal partners in PCM adoption, although they do not have much 
power. They strongly wish for a development of new treatments. Therefore patient as a 
stakeholder in PCM adoption has lower power, legitimacy and high urgency.  
The power, legitimacy and urgency will together decide the salience of each 
stakeholder. The salience of main actors in the technology acquisition/development phase 
is described as following, which provides the basis for stakeholder managerial actions.    
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Table 3. 
            At current stage, researchers in the program represent the highest salience and are 
the driving-force for the PCM adoption. They have strong motivation, knowledge and 
resource for technology adoption. They are in close contact with all the stakeholders and 
can mitigate the risks for each group of actors. Therefore, they act as group of technology 
champions and in collaboration with leading-edge clinicians and strive to build up a 
workable model integrating representative of major actors in Norwegian healthcare to 
demonstrate the efficacy of PCM. A champion as a manager can promote adoption by 
developing technology accommodating to the country specificity, balancing the 
relationship of various stakeholders through resource allocating and decision making. 
This data suggested the following proposition:  
Proposition 3: The technology champions as managers advocating an innovative 
technology are at the center nexus of early technology adoption in the Norwegian 
healthcare.  
4.2.3 Organization	
The PCM project is led from OUS and the infrastructure is established at the same 
institutions where both project leaders and employees have extensive experience with 
sequencing technology from the previous FUGE project. With this set up, the 
infrastructure is located at the only national cancer-specialized hospital surrounded by the 
high profiled cancer researchers, and is managed by experienced national experts. The 
necessary resources (expertise and infrastructures) for the major targeted users of this 
PCM technology have been organized in the harbor where innovation for cancer 
treatment will advance. This organizational setup will in principle shorten the time to 
PCM adoption in clinical use, as resources are arranged in the best way both horizontally 
and vertically, which largely reduced the time aquiring the  high technological expertise 
Stakeholder Power Legitimacy Urgency Salience
Researcher High +++ High +++ High +++ High +++
Clinician High + High +++ High + High++
Patient Low High +++ High +++ High +
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for doing sequencing analysis. The alignment of the organizational strategy with the up-
to-date technology infrastructure facilitates the technology adoption in practice. 
Organizational readiness is established in several ways for PCM adoption. For 
instance, the culture for using the technology in research has been well shaped in the 
institution. Seminars and research meetings are held on a regular basis pertinent to both 
clinical and research use of existing and new technology. Informal discussions during 
lunchtime have built a good rapport and communication between biologists and 
oncologists and fostered a favorable environment for the innovative solutions to complex 
clinical problems. This is good for encouraging all the employees to make use of this new 
technology. In Norway, there is a relatively low hierarchy at workplaces and the 
teamwork spirit is important. All the employees are respected and treated equally, also in 
the decision making process. Staff members’ participating in the discussion can enhance 
the familiarity about the technology, hence technology adoption.  
Three types of communications were observed in the early PCM adoption: 
patient-physician, physician-molecular biologist and biologist-biologist. “Cancer patients 
are the most loyal partners in the course of PCM adoption. They are willing to take new 
biopsies for a new DNA sequencing test as the oncologists recommend, and sign all the 
general patient consent without any problems”, as an manager described. A generally 
good interpersonal communication between the patients and the oncologists is apparently 
established. Meanwhile, several good communication channels between biologists are 
established through professional networks and meetings. Regular meetings (2 times per 
year) are held among the principle investigators and the collaborative clinicians. In 
addition, newsletter, mailing list, sample list and forum on NCGC website are important 
channels to communicate and coordinate nationally with the professionals. Although 
there is no special bioinformatics department, there are quite handful bioinformaticians 
working in the same institute and helping with data analysis. Researchers and clinicians 
can get consultancy about data analysis using the available technology/software and 
interface. However, “the consultation may not seem sufficient when researchers or 
clinicians have to deal with complex and tedious data analysis by themselves with current 
available resources,” said a researcher. The situation can be worse for an oncologist when 
she/he tries to grasp the essential information for making a diagnosis and prescription, as 
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oncologists are generally less familiar with genes and their implications, nor with the 
different computing programs. They feel difficult to get real understanding about the 
technology, even they have a desire to. The worst situation is between the pathologists 
and the biologists. “The meeting among pathologists is extremely boring, and 
pathologists have been invited to our meetings, but they seldom showed up”, said a 
biologist and executive. As a pathologist mentioned that they are used to the traditional 
diagnosis and have low motivations to listen to an algorithms’ instruction for diagnosis. 
A better communication shall focus on establishing a mutual understanding between how 
the traditional and PCM technology can be good supplement to each other for making a 
timely and precise diagnosis and prescription for cancer patient. Otherwise, the lack of 
sufficient communication between physicians and biologists can be a bottleneck for the 
PCM adoption/implementation. 
Several external organizations have collectively worked together to attract more 
societal and industry attentions to the PCM technology. A number of collaborations and 
partnerships are formed. Oslo Cancer Cluster (OCC) as one of the “Norwegian Centers of 
Expertise” is dedicated to accelerate the development of new cancer diagnosis and 
medicine through collaborative networks, and public policy, among others. OCC brings 
both academy and industry partners within and outside Norway together to evaluate their 
interests and to foster the possible engagements. The Norwegian Cancer Society (NCS) 
has worked extensively through open meetings, debates and free concerts around the 
whole country. “These events as important educational vehicles have made a good 
publicity for PCM, cancer research and patient care. NCS raised a good donation for 
cancer research and clinic applications. NSC has now received gradually more 
applications from clinicians in response to our application calls. Clinicians are more 
aware and participating in PCM field.” Connection with the external organizations is 
helpful for researchers in academy to “get to know the real world and what the real needs 
are. This has also made our research more useful in the sense of meeting the real world 
need,” as a researcher said.  
Some pharm companies have formed partnership within PCM program. They will 
contribute to the technology integration for making a standardized and scalable routine 
within Norwegian healthcare. These industry partners are mostly small Norwegian firms, 
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where their core competence is supplementary to academic and clinical actors. Although 
some international large pharm companies have interests in the partnership, they 
characterize Norwegian pharm investment environment “as small and quite different as 
the other countries such as in England and Germany”, where the investment environment 
is more dynamic and mature. In addition, the available small sample size for PCM is 
limiting the potential interest of investment for pharm companies. Currently, the public 
funds remain the form of financing source. The possibility for the participation of 
industry partners in this program is worth further development.          
As a tradition in Norwegian healthcare system, the Ullevål hospital has the power 
for decision-making regarding to diagnosis. In this way,  the working efficiency for 
cancer diagnosis using PCM is largely reduced, as the technology is especially for cancer 
patient and implemented in cancer-specialized Radium hospital, apart from Ullevål 
hospital. “So there is a power distribution problem between different hospitals”, said an 
executive in interview. The Radium hospital is the only cancer specialized hospital within 
the country and it is an organization pursuing clinic, research and education activities.  
Most of those oncologists working in the cancer departments in the other regional 
hospitals are trained in the Radium hospital. The Radium hospital has gathered 
predominant competent resources in the country and is naturally the trial site for PCM 
adoption, including clinical decision-making. The experience and lessons learnt from this 
prove-of-concept phase at the Radium hospital could be integrated into a more mature 
model for PCM implementation later or in other hospitals.       
4.2.4 Fit	between	Human,	Organization	and	Technology						
The fit between these three factors are recognized. The presence of a strong pro-
adoption coalition of interests facilitated the both decision-making and actual PCM 
adoption. The organizational readiness enabled a relatively quick establishment of 
sequencing platform, thus a quick initial adoption phase. The strong user acceptance from 
researchers and clinicians laid a foundation for technology uptake, while the difficulty 
with data analysis, interpretation and limited computing accessibility are the internal 
limiting factors for technology implementation at a larger scale. The present operational 
manner in the local adopting system represents a way of creative technology 
customization in terms to the way and scope PCM works. A better internal fit between 
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technology and user need could be further achieved through development of a user-
friendly highly integrated informatics solution. New skills and competence will be 
acquired along the process of developing platform. Therefor adoption of individual 
technology may locally change the shape of the adopting systems themselves by creating 
precedent, developing new skills and empowering certain groups rather than others. For 
instance, the previously established FUGE platform has paved way to establishment of 
the PCM platform at the Radium hospital. The adoption of a given innovation can change 
the capabilities, interests, values, and power distribution of the adopting system and 
render it more likely to adopt future innovations.  
The fit between the human and organization has been facilitating the adoption 
process. The entrepreneurial-oriented scientists work in the hospital research institutions 
and in close contact with hospital clinic entity. This close connectedness creates a 
favoring information flow for these scientists to comprehend the need for a new 
technology for cancer treatment. The program-based technology adoption can effectively 
gather multidiscipline-professionals working in the same framework and promote 
adoption across the whole healthcare system, while without changing the organizational 
structures and being able to respond with great flexibility. Under this flexible framework, 
the program managers have prepared the appropriateness and conditions for good 
practice, balanced relationship between various stakeholders, and participated in the 
product development, trial design and drove the process forward. They acted as both 
managers and champions systematically advocating the technology adoption in 
accordance to the national strategy.  
A good organizational fit across organizations is more difficult to reach and will 
take long time to obtain. For instance, cancer registration (kreftregisteret) has 
responsibility to establish a complete population-based cancer clinical database. In the 
future when PCM is implemented, this data will be more enriched with more molecular 
markers and mutations. Such database in principle is extremely powerful, for example, 
for designing clinical trial for testing new drugs. However, in the current system cancer 
registration is only able to return patients’ information to doctors and researchers, when 
the patient is in Oslo. Due to complicated ethical issues with different level of patient 
consent, cancer registry is not able to return patients’ information to doctors when the 
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patient is in other region of the country. “This will largely reduce the power of our cancer 
registry. And we hope a new system can be developed in the next few years. When we 
talk about a PCM national platform, we need a system with a national standard to be 
applied nationally”, said the head of cancer registration.  
Although the cost-effectiveness cannot be reached in current approach due to the 
small sample size, PCM can inform decision making for specific patient with molecular 
characterization for right diagnosis and treatment and at same time avoid unnecessary 
treatment, which will save both patient’s time and unnecessary cost. Therefore, at this 
early stage, delivering quality assured service will be the initial net positive benefit, 
which will continuously improve to become cost-effective along the technology 
advancing. The other positive net benefits includes that 1) clinicians will gradually 
acknowledge and adapt to the concept of PCM, therefore providing better health service 
to the nation, as a clinician said in the interview; and 2) researchers will be able to 
discover and validate biomarkers as actionable gene for cancer treatment based on 
Norwegian data; and 3) these data will be returned to contracted industry partners for 
drug-discovery.      
4.2.5 Broad	Context		
Technology advances have enabled the development of a model of discovery, 
translation and delivery for personalized treatment. Patient is the most fundamental 
partnership in PCM adoption, but they have lower power. There are important ethical, 
legal and social implications regarding the selection, consent and use for patient 
information both in clinic and further research.          
Understanding how to afford trust and to provide adequate support for ethical 
concerns relating to the handling of sensitive DNA data is a particular challenge for PCM 
adoption. Genetic code represents personal information. If information about a person's 
genes is treated as the same way as with other health information - so for example, 
insurance companies can gain access to them - or should it be regarded as particularly 
sensitive information? This is an ethical question and everyone has a different opinion 
from her/his culture background and experience. Ethics is necessary at the moment of 
moral content is no longer self-evident. It may be because a new event or insight casts 
doubt on our moral convictions, or it may be that a new issue arises when our morality no 
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longer has any clear solutions. The latter is often the case for biotechnology issues: these 
issues are so new that few have clear moral views about them. “Biotechnology Advisory 
Board has responsibility to create debate and gather information around biotechnology 
related ethical issues. We collect information about technology, different opinion/values, 
as well as consequences and risks for what we are doing in our society. PCM technology 
will produce a huge amount of data. Who owns this data? We give advice to department 
regarding how to handle this data in a sensible way, what should be known and how to 
interpret the law in order to take care of the future value of data. We, a working group 
with representatives from healthcare system, started revising “Norwegian Biotechnology 
Act” in Dec. 2011 and now the new Biotechnology Act is proposed to the department and 
hope it will be in action soon.” said a senior secretary in a deep interview.       
           A reimbursement device with national coverage and emphasis on cost containment, 
efficiency, and affordability will facilitate the PCM adoption and implementation after its 
demonstrated therapeutic benefit and cost-effectiveness.  
Proposition4: The alignment of stakeholders’ perceived benefit in a broad context 
will influence the trajectory of technology adoption.   
4.3 Roll	Out‐Cross	the	Chasm	
PCM is hitherto adopted in Oslo with established infrastructure and some small 
clinical trials running by small number of key investigators, which demonstrated a good 
trialability of the concept and the technology. According to Moore, these key 
investigators are characterized as early adopters and are the technology enthusiasts and 
visionaries. They possess great desire to explore the technology and have extraordinary 
influence in organizations. In the process of PCM adoption, these early adopters are the 
program managers, who actively work as champion on advocating the use of the 
technology. Making the transition between visionaries (early adopters) and pragmatists 
(early majority) is the most difficult step and is the chasm that Moore refers to. As the 
program advancing, the need of preparing for crossing the chasm has become more 
salient. Visionaries and pragmatists have very different expectations. To successfully 
cross the "chasm," managers should explore those differences and use some techniques. 
In the case of PCM, the key managers are visionaries and the rest oncologists, 
pharmacists and researchers belong to the main stream pragmatists. The main difference 
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in mindset and behavior between these two groups includes user’s perceived usefulness, 
understanding and intension to use the technology. 
The managers recognize this difference very well and have set out a series of 
activities on promoting clinician’s cognitive acceptance of PCM. These clinicians as 
pragmatists have insufficient knowledge of genetics and genomics and are waiting for 
more evidence before making their own choice. The program managers have set up a 
wide range of multi-discipline seminars combining the theory and practical application of 
the technology at different levels. Several external organizations (Oslo cancer cluster, 
Kreftforeningen) have also together built up a platform for discussions. Clinicians are 
thus able to receive relevant information directly from various vehicles. Those successful 
cases led by peer oncologists have clearly shown how an oncologist could use the 
technology and benefit from it, thus have been an influential education for oncologist. 
According to kreftforeningen, they receive gradually more grant applications from 
oncologists. This indicates that more oncologists get to understand the power of the 
technology and would like to proactively seek opportunities for using it. Once some 
clinicians are educated and get more good experience, they will gradually become 
ambassadors for the marketing the technology to the next group. In this way, current 
clinicians will progressively receive better knowledge about PCM and get more involved 
in technology uptake. In addition to oncologist, genomic consultant is responsible for 
patient consultation regarding to interpretation of genomic data. There are currently only 
30 genomic practitioners in the country, according to legeforeningen. This seems an 
insufficient number when PCM is implemented nationally. Therefore a long term strategy 
should include more investment in biomedicine education in medical schools to educate 
more such specialized professionals.  
The ease use of technology is a factor influencing the technology acceptance. A 
continuous endeavor for delivering a user satisfactory technology is observed both for the 
sequencing and IT solution within the available resources. During this process, users are 
closely involved and some developers are the users, thus the users’ needs can be grasped 
and reflected. It is still wise to remain alerted to those technology advances and drivers in 
the market, thus a technology better fitting to user’s need could be integrated through f.e. 
strategic alliance. Currently, industry partners are hesitating to invest due to “the bad 
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images of Norwegian biotech compared to the international pharma environment, such as 
in England and Germany”. Norwegian scientists, on the other side, point out that “the 
country should use our limited public funding to develop our own competency instead of 
financing international pharm industry. We could have collaboration with industry on 
some era, but not within the core of the business.” 
There is a requirement for an entrepreneur-orientated thinking for recognizing our 
strength and weakness in the core of the business, and be clear with the field where we 
need and could partner with others. This strategic analysis would guide a creative 
approach towards a win-win partnership with industry partners. To date, designing a 
highly integrated IT solution that better meets users’ needs could be a field where 
industry collaboration per se as welcome, for example.  
This program has been financed through public funding. In this top-down strategy, 
a continuous funding will be more secure when a clinical utility can be demonstrated to 
the stakeholder such as clinicians and payers. At this stage, exemplar showcases have 
given the impression how the technology is working. Forming a standard test protocol in 
guidelines will be essential for technology implementation nationwide, as well as for 
determining pricing and appropriate reimbursement for PCM. This information would be 
indispensable for establishing a complete business model for providing this service.  
4.4 Facilitators	and	Barriers	
        Based on the theoretical grounding, this empirical research revealed the facilitators 
and barriers for PCM adoption in the Norwegian healthcare system as in table 4.   
 Facilitators Barriers 
Technology User perceived usefulness, user involvement and 
interaction, Tialability, obsovervability 
Complexity, insufficient 
end-user support, cost, 
incompatibility, limited 
sample size  
Organizational Single healthcare system, professional communication 
vehicles, tight collaboration between researcher and 
clinician 
Limited organizational fit 
across organizations, 
limited industry 
collaboration 
Human and 
Social 
Champion and leadership, dynamic clinician-patient 
relationship, learning capacity, peer influence 
Cognitive boundary for 
clinician, oncologist and 
pathologist 
External Government support, public finance, trend of technology 
development, good collaboration with relevant external 
organizations, biotechnology act in place  
Lack of reimbursement 
mechanism 
Table 4. 
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5. Discussion	and	Conclusions	
Healthcare organizations face tremendous pressure to continuously provide high 
quality health service with well controlled expenditure in most countries. Prior 
experience in many industry sectors demonstrated that disruptive innovation is the most 
powerful force to meet the need of “cheaper, simpler, more convenient product or service 
that starts by meeting the needs of less demanding customers” (Christensen et al., 2000). 
There are two mainstreams of technology innovation in healthcare system: technology 
towards high end for specialist use to cure the complex diseases by simplifying complex 
problem; and technology towards the low end for patients use and thereby relieving the 
general practitioners and professionals, so they can be better focus on the more difficult 
problems (Christensen et al., 2000). PCM fits into the first trend. However, healthcare is 
a change-averse industry with inherited barriers for innovations. These barriers within 
economic, organizational and behavioral dimensions will impose challenges at various 
degrees for innovation uptake when a disruptive change provides an opportunity for new 
entrants or ideas to challenging existing stakeholders within a specific healthcare system 
(Phillips and Garman, 2006). The resistance from existing stakeholders will be 
manifested in a unique technology adoption pathway in a specific healthcare system, 
which intersects with external and internal factors and the nature of involved technology 
then results in distinct adoption trajectories. 
The Norwegian healthcare system is often described as a decentralized national 
health service with universal coverage. Regional health authorities oversee all hospitals in 
their region, and are led by an executive board, appointed by the Minister of Health. The 
most important regulatory mechanisms for the healthcare system in Norway are thus the 
government providing finance, presenting aims and working plans to the hospitals, and 
the municipalities with similar responsibility for local primary care (Morland et al., 2010). 
The Directorate for Health is responsible for National Clinical Guidelines, while 
Medicine Agency is responsible for regulating and reimbursing drugs for primary care. 
The health technology assessment (HAT) has responsibility to systematically evaluate the 
medical, economic, social and ethical implications for the introduction of new 
technologies in healthcare (Morland et al., 2010). National Council set national priority 
and quality improvement in healthcare. Council selects topics brought forward by 
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members and can recommend solution, after thorough evidence-based assessment, to 
Directorate for Health for resolving a critical problem in health (Morland et al., 2010). 
This healthcare structure sets a stage for a top-down strategy as a feasible technology 
adoption approach. At the same time, it underlines the possibility for proactive actions 
from different “levels” of healthcare sectors.   
The first proposition draws attention to the importance of alignment between 
external environment and the internal need for adopting a new technology in the process 
of opportunity discovery. The researchers and clinicians discovered the opportunity 
though identifying new internal desires and new area of value, searching external 
environment and matching external factors to the internal needs. Consequently, the 
opportunity was recognized as national priority and the “agency” was brought to exploit 
the opportunity. The case of PCM represents an exemplar model on how a top-down 
strategy could be an effective mechanism for technology adoption for a high end use, 
when combining the bottom-up information. In this strategy, Norwegian healthcare 
organizations leverage the resources and take advantage of the benefit of intrapreneurship 
through encouraging initiative, identifying opportunity, establishing technology 
champion, developing appropriate collaborations and alliance to exploiting the 
opportunity, which are the critical components for a successful innovative technology 
adoption in the Norwegian decentralized healthcare system.          
The group of researchers and clinicians together as a team discovered the 
opportunity under a context of risk as it is currently unknown what the feasible model for 
PCM adoption and implementation is. An appropriate model can be only synthesized 
after experimenting. Scientists and clinicians can be regarded as entrepreneurs, who use 
imagination and judgment to interpret economic data and anticipate market conditions to 
actively formulate and solve new problems (Alvarez and Barney, 2007). According to 
Kirzner, these researchers and clinicians are “alert” people and aware of opportunities 
created by exogenous shocks-technology advances. They are more proactive and 
associated with more information accessibility and have cognition towards innovation 
(Kirzner, 1999). The scientists and clinicians have recognized the problem with cancer 
patient that underlines the need for a more accurate molecular diagnosis and prognosis 
technology. They made a comprehensive judgment grounded on the cancer research and 
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genome analysis from recent technology advances and then creatively proposed that the 
PCM could be an idea solution to be exploited. The knowledge accumulation in cancer 
research and sequencing technology advances are the exogenous impetus for clinical use 
of PCM. During this process, the group has collected opinions from the key stakeholders 
and collectively exercised their subjectivism judgment to recognize the opportunity and 
subsequently took a proactive action for gathering resources and necessary support. 
Subsequently, their proactive lobbying has made a good publicity among the 
governmental decision-makers and the governmental funds were granted.   
Prior to technology adoption, a national advising group has set up the guidelines 
regarding to the visions, scientific basis, and how to gather competence to exploit the 
opportunity and reach the goal. According to this strategy, the opportunity is exploited 
within healthcare system as a national program in a manner of tightly collaborating with 
academic research institutions, universities, hospitals and Norwegian industry with an 
aim to provide a new and more accurate diagnosis for cancer patient at specialist care 
entity. This collaboration brings together the best competence in multi-discipline field 
including all the stakeholders to carry out the mission with reasonable public funds. This 
partnership allows the exercising of entrepreneurship without an actual enterprise. Such 
program can be regarded as an inter-entrepreneurial activity within healthcare system for 
an improved service through adaptation of an innovative technology (Christensen et al., 
2000). This strategy fertilizes entrepreneurial activity in our healthcare system in a cost 
effective manner.  
The mission of Norwegian healthcare and university hospitals is firmly rooted in 
the service, education and research for patient care. The resource is controlled with a 
governmental and societal consensus towards this mission. Therefore the role and 
responsibility of healthcare organizations and their employees are subject to myriad 
regulations, professional and historical factors, which will encumber changes to the 
hierarchical system and participants (Phillips and Garman, 2006, Morland et al., 2010). 
The Norwegian healthcare is founded by public funds and limited private donations. This 
non-profit healthcare operates differently from for-profit ones. This very nature is in 
conflict with the environment favoring entrepreneurship, where the primary emphasis is 
exploiting opportunity for individual achievement and rewards. However, the healthcare 
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has a need for better performance with high efficiency and quality service. The better 
performance can be achieved through an internal test within a relatively high hierarchical 
organization - namely intrapreneurship. Often a public fund is put up as risky money for 
exploitation of new ideas and researches within health care, such as the American NIH 
fund. The NRC provides such a resource for national priority within the health. Within 
the project, the new method and the new model of service can be created and tested for its 
feasibility. The mission of intrapreneurship is a better performance of the organization 
resulting from a group of employees, rather than personal achievements.  
The second proposition points out the characteristics of the technology are the 
core which interacts with its soft periphery and together determines the adoption pattern. 
PCM technology can be roughly described as a combination of sequencing technology 
and Highly Integrated Informatics Platform (HIIP). Facilitating the acceptance for both 
technologies is necessary for the PCM adoption. At the organizational level, the process 
for the PCM adoption can be conceptually delineated into several distinct phases, ranging 
from technology assessments to actual technology acquisition and implementation. Often 
these phases are concurrent and overlapping. The practical realization of the PCM 
adoption is led from OUS with key investigators from different working places in the 
field. The advantage of this structure is that the technology platform can be established at 
the suitable institutions, where organizational, cultural and human resources fit best to its 
functions, thus largely reduces sunk cost for operation. For example, the sequence 
technology platform is established at the previous FUGE sequencing platform and 
essentially the same technology is employed for PCM. The staff has already gained 
extensive experiences with the technology and this technology has been well accepted 
within research environment when the PCM starts. These are the major reasons this 
specific technology is chosen -the good fit among human, technology and organization. 
Therefore, the phase of technology assessment is shortened and processes quickly run 
into the technology acquisition and implementation. Comparing to the sequencing 
technology, the adoption of HIIP is following more typical phases. Currently, a mature 
HIIP efficiently addressing users’ needs for the PCM has not yet adopted. A Norwegian 
industry partner is responsible for the development of this HIIP integrating oncology, 
genomic research and pharmaceutical advances for the cancer treatment. Furthermore, the 
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decision support tools including electric medical records will be needed for data 
interpretation and point-of-care decision making. Development of such a HIIP will go 
iteratively from assessment to acquisition and implementation for several cycles. 
Linking to the literature, Technology Acceptance Model (TAM) suggested that 
user perceived usefulness and ease of use are the decisive factors for users’ actual attitude 
to accept a technology. External factors embedded in environment and organization are 
jointly influencing users’ attitude (Davis et al., 1989). The better fit among technology, 
human and organization factors will lead to better acceptance of a HIIP, therefore the 
willingness to use technology (Yusof et al., 2008, Yusof et al., 2007).  
The end users of the PCM include clinicians, oncologist, pathologists (COP) and 
molecular biologists. Our study shows that except the molecular biologists, the rest group 
of users has very limited knowledge and experiences about the gene and the 
bioinformatics. The COP users generally perceive the PCM positively for the future 
patient care and are open to the PCM adoption, despite with recognized conceptual and 
practical challenges. Currently, the group of COP lacks evidence-based clinical 
information for the actual technology acceptance. This is in consistent with the previous 
survey from US and Canada (Bonter et al., 2011) where lack of education and evidence-
based information is one of the major barriers for PCM adoption. To lift their interest and 
level of understanding is critical for the PCM acceptance, as these groups of users will 
participate in the diagnosis and make treatment plan. Previous research showed that 
attitude of key personnel is an important factor in technology adoption in an organization 
(Yarbrough and Smith, 2007). Proactive cultivation and management along time could 
reinforce a favoring environment and lead to the  technology acceptance. Professional 
seminars and workshops with successful showcases are effective vehicles for facilitating 
communications about the technology and its application. The peer can largely influence 
the attitude towards a PCM technology adoption (Ginsburg and McCarthy, 2001, Bonter 
et al., 2011). The key investigators in the program have been actively working for 
promoting user-perceived usefulness from technology acquisition and implementation to 
software development, from managing the project to educating clinicians.  
Perceived ease of use (PEOU) is regarded as important factor for the choice of 
technology adoption (Davis et al., 1989). PEOU was inversely correlated with the 
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adoption, especially at the early assessment phase. In advanced adoption phases, PEOU 
does not appear as important as in the preliminary assessment phases. Technology 
appraisal may be considered increasingly manageable over time by trial use and end-user 
training, which would produce scientific evidences and justifications necessary for the 
underpinning the essential technical knowledge. In our study, DNA sequencing and PCM 
are perceived as complex technologies, especially for the COPs who are unfamiliar with 
the context. They are unable to use it by themselves. In collaboration with biologists, 
some oncologists in the program have started small clinical trials within the certain 
cancer types. Along the trial, these oncologists get better understanding of the technology 
and communicate to other clinicians through seminars. Effects of trial use and training 
are thus enhanced with adequate communication to individual physicians.  
The proposition 3 links to the role of the technology champions in the process. 
The PCM program is managed by a group of key investigators consisting of biologists, 
clinicians and oncologists. At the same time they are recognized as technology 
champions advocating and customizing the technology in the early stage. Therefore they 
have important functions from management to technology development and adoption. 
According to the stakeholder theory, managers have a unique position at the center of the 
nexus of contracts, namely they are the only group of stakeholders who enter into the 
contractual relationships with all the other stakeholders and who also directly control the 
decision-making apparatus. Managers’ values and perceptions are vital for identifying the 
stakeholder salience and deciding which stakeholder should receive managerial attention. 
They collectively make strategic decisions and allocate resources in a manner of most 
consistent with the main stakeholders along the dynamic process. At the same time, these 
key investigators are the early adopters characterized as the educated community leaders. 
They build and test out the model to provide new services through adoption of the 
technology. According to Everett Rogers (2008), the most difficult gap for technology 
adoption is the adoption from early adopter to majority. The majority group is more 
conservative but open to new ideas. They are active in the community and have peer 
influences. When an individual considers adopting a new technology, the process goes 
through a sequential stage of awareness, interest, evaluation, trial and adoption. Hence, 
the early adopters-the technology champions should deliver the right information to the 
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possible majority adopters, cultivate the interest through trials and lead to final adoption. 
The public meetings and debate widely organized in the society by other organizations 
such as cancer registration and Oslo Cancer Cluster have aroused huge publicity for the 
PCM, which will together foster an environment for the PCM adoption. This whole 
process will create a bandwagon effect for a majority adoption in the organization. 
The literature suggests that the innovation adoption and diffusion process may 
take a variety of different forms, as every adoption process is driven by various 
interconnected rational, institutional, and political forces within organizations. These 
factors interact with each other and with innovation over time to produce particular 
patterns of adoption (Rogers, 2003, Rye 2007). This single case is representative of 
technology adoption in the Norwegian healthcare system. It is involving multi-discipline 
collaborations and actions from the health department, hospitals in all the health regions 
to the industry partners. The issues in the aggregates of the case represent the theory of 
technology adoption in healthcare. This empirical study has demonstrated some special 
aspects for high-end use technology adoption in Norwegian healthcare system, which can 
be generalized to the theory.        
Entrepreneurial orientation that generally includes three dimensions: 
innovativeness, risk-taking and proactiveness, is described as “the process, practices and 
decision-making activities that lead to new entry” (Lumpkin and Dess, 1996). New 
product may lead to firm’s better performance, thus firms may benefit from adopting an 
EO (Rauch et al., 2009). On the other hand, firms pursuing higher EO are faced the 
downside of the decision involving risk-taking and allocation of scarce resources, which 
strongly calls for evidence-based strategic management. In this top-down strategy, it is 
clear that government policy governs innovation adoption and knowledge utilization by 
focusing attentions and resources on certain priorities (Dopson et al. 2002). The strategic 
positioning and significance of innovation set by the national priority catalyzes 
technology adoption and functions as a control for risky initiatives. The scientists with 
higher EO have a clear role in participating in formulating creative strategy for decision-
making and technology leadership. They are at higher position, with greater tenure and 
greater experience, which could mean legitimacy and knowledge for navigating political 
waters, and thus, could be positively associated with adoption. Denis et al. (Denis, 2002) 
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emphasized the importance of the interests, values, and power distribution of the adopting 
system on the ultimate adoption of innovation. In this case, a combination of top-down 
and bottom-up strategy has allowed applicable, evidence-based technology to be 
prioritized for a feasible adoption. In the situation where only either top-down or bottom-
up strategy applied, it can lead to poor applicability after adoption (Ole Frithjof Norheima, 
2001) or fail to raise interests for the adoption for mature technologies with rich scientific 
evidences (Lemieux-Charles, 2006). 
The organizational culture is the context in which EO activities occur (Wales et 
al., 2011 ). Local conditions have influences in terms of technology choice, available 
technology expertise and organizational structure. A technology which requires minimum 
change will be the best choice for gathering technology expertise and will suit and 
function best in the current organizational structure. Organizational attributes have been 
the most examined category of the technology adoption researches. Organizational 
process influences individual, team-based and organizational learning. The sustained 
entrepreneurial productivity requires internally knowledgeable team entrepreneurship and 
an organizational environment (including effective governance) that encourages cognitive 
heterogeneity, positive team dynamics and resource learning (Foss et al., 2008). The 
greater professionalism, specialization, internal communication and complexity are 
positively associated with innovative behavior. The innovative behavior typically 
depends on the combination of (1) which organizational actors (and in which 
combination of consensus and conflict) are differentially involved, and hold change 
values; (2) the type of organization in which such combinations of involvement, attitudes, 
and values take place; and (3) the type of innovations that are being researched (Rye and 
Kimberly, 2007). These combinations within the organizations influence the decision-
making activity, thus the adoption. In the case of the PCM, improvement of cancer 
treatment is the common goal for both clinical and research entities in the whole Radium 
hospital. The cognitive heterogeneity between clinician and researcher will facilitate the 
generation of new ideas, but may impose challenges for the technology adoption, under 
the situation when this specific technology challenges the value of a specific routine of 
certain group of people.  
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Previous researches demonstrate that an entrepreneurial style per se is not 
necessarily desirable in all situations. The positive (or negative) influence of an 
entrepreneurial style on organizational performance is defined by certain internal and 
external characteristics. Organizational performance will be enhanced when there is a 
good “fit” between management style and various contextual factors (Dalton et al., 1980).  
An entrepreneurial top management style has a positive effect on the performance of 
organically-structured firms and a negative effect on the performance of mechanistically-
structured firms (Covin and Slevin, 1988). Healthcare as a whole can be generally 
regarded as risk-averse and passive hierarchical organization, which is by definition not 
“an entrepreneurial firm”. However, within the Norwegian hospital institutions, the 
researchers are inclined to favor changes and innovation in order to obtain competitive 
advantages and compete aggressively with international scientists. The research 
environment can be characterized as flexible, informal, authority vested in situational 
expertise and facilitate innovations and new ideas. A good “fit” between EO and organic 
research environment is aligned. Thus the top management with strong EO in the 
research environment can enhance the organizational performance. The top management 
is the main driving force for medical innovation in the country. The case of PCM 
adoption demonstrates how they collectively promote the adoption of innovative 
technology; make a customized technology in research environment ready for clinic 
implementation. This is an efficient pathway for the high-tech adoption in the Norwegian 
healthcare.           
Innovation characteristics can influence the adoption. The more complex and 
more divergent interests between the stakeholders and the management, the slower 
technology adoption will be. For instance, the users of PCM technology include a variety 
of professional groups who practice with their own organizational cultures, agendas, and 
questions. We can expect the usual conflicts around mobilization of resources and 
coordination of effort around technology adoption to be intensified. We gained access to 
the PCM technology through the purchase of a sequencing technology and building up 
own sustainable competence along practice. The high technology expertise is required for 
customizing and developing the technology. So far, this is a strong researcher-driven 
process. How this manner of technology access and the interaction between 
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organizational and innovation characteristics will influence the tech adoption and 
implementation trajectory in clinical entity deserve further research. 
Connections between organizations are generally regarded as adoption facilitating 
factors (Rye and Kimberly, 2007).  Higher levels of each of these connections (or in the 
case of network position, a more central or dominant) would facilitate the adoption. 
Normative and institutional pressures may facilitate the adoption to a greater extent for 
the later adopters than for the earlier adopters.  Social and cognitive boundaries between 
medical professions and researchers contribute to the slow spread of innovations. Greater 
network interaction and centrality are hypothesized to be associated with an increased 
likelihood of adoption. Network relationships influence organizational adoption at the 
individual level (Rye and Kimberly, 2007), which can effectively create a bandwagon 
effect in the organization. Technology champions at higher position in the community as 
in this case have worked as boundary spanner through their network to promote the PCM 
adoption from decision-making to actual adoption.  
In summary, this narrative analysis provides empirical data about the critical 
elements that affect innovative technology adoption in the Norwegian specialist 
healthcare. The case of PCM adoption demonstrates that when a technology champion 
participation coupling with a top-down, program-based strategy could be an effective 
mechanism for the technology adoption for high end use in the Norwegian healthcare, 
especially when competence across multidiscipline needs to be acquired for a complete 
technology adoption through the technology customization and development, such as the 
development of a good HIIP. A tight collaboration between research institutions and 
clinics is a feasible manner for building up our sustainable capability for providing better 
medical services. In this way, we can efficiently leverage our resources to deliver new 
services without the requirement of organizational changes. The entrepreneurial-oriented 
scientists as both technology champions and managers can facilitate to set the national 
priority and formulation of the technology adoption strategy as a response to the 
technology development and internal unmet needs. The information from both research 
and clinic serves as the basis for the technology adoption decision making activity. The 
loosen connections between multidisciplinary professionals and different organizations 
including industry can foster entrepreneurial-oriented thinking, therefore favoring the 
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uptake of new technology. The HOT-fit has been recognized for the initial adoption. The 
key investigators as technology champions are the vital drivers for technology adoption 
through developing a framework with a good HOT-fit and implementing a strategy 
within this framework. The extraordinary environment, including the strategic and legal 
frameworks, is prepared for the tech adoption in this top-down approach. A more user 
friendly software and a better user support for data analysis and patient management are 
demanded for the further technology adoption. The cognitive gap between the early 
adopters and majority adopters should be remediated through the adequate 
communication and training by using multiple communication vehicles. 
Drawing on this data, we find evidence to support that technology adoption in the 
healthcare is influenced by the nature of the problem being addressed, the technology, the 
local adoption system, the health system characteristics and the broad context in which 
the adoption happens, as proposed by Atun (2009). The nature of the problem being 
addressed such as social narrative, urgency and socio-economic burdens due to the 
problem will influence the necessity and rate at which an intervention designed to address 
it (Atun et al., 2010). New technology is introduced in response to the endogenous and 
exogenous actions or stimulus. Perceived attributes of technology, such as usefulness, 
ease of use, trialability and observability will influence the speed and the extent the 
technology is going to be adopted through intersecting with the local adoption system. 
The local adoption system refers to key actors and institutions with varied interests, 
values and power distributions in relation to the technology adoption. Each of these 
stakeholders has different perception about the benefit and risk related to the technology, 
consequently different incentive, altitude and role in the process of technology adoption, 
which will collectively decide the “receptivity” for new technology (Atun et al., 2010). 
Strong EO of top management is associated with the PCM technology adoption. 
Alignment of regulatory, organizational, financial factors and social-norms facilitates the 
PCM adoption.  
 
 
61 
 
6. Implications		
The following section focuses on the both theoretic and practical implications that 
this study might lead to. 
6.1 Theoretical	Implications	
We proposed an integrated framework (Figure 3) incorporating the technology 
adoption, TAM, HOT-fit and stakeholder theory to portrait the pathway of PCM adoption 
in Norwegian healthcare and point out the critical elements at each phase. 
This study provides several implications for researchers: 1) our empirical data 
indicates a linkage between strong entrepreneurial orientation (EO) and technology 
adoption in Norwegian healthcare. However, EO is not inherently associated with 
positive performance. It is therefore interesting to study how the concept of EO could 
have a moderate effect in relation to a technology adoption or adapt to changes in the 
context of the large, established, decentralized healthcare system. Under which 
circumstance (what type of technology, who is engaged at what stage), exercising 
intrapreneurship can be a practical general model or instrument to promote technology 
uptake and functional integration in a specific healthcare setting? 2) Top-down 
intervention is an efficient way for technology uptake in a decentralized healthcare 
system. There is a need for in-depth understanding of gaps along technology adoption in 
the different healthcare settings, when a top-down approach is heavily involved.  
6.2 Practical	Implications	
The healthcare system by nature is with high hierarchical structure and 
standardized procedure, which shape an environment not favoring innovation and new 
technology. The PCM case provides some practical implications for healthcare 
executives and policymakers in relation to technology adoption. First, internal attitudes 
and behaviors associated with EO across differing organizational level and unit can foster 
innovation and new technology adoption, especially when multi-organizations are 
involved in acquisition of new technology in healthcare system. EO attitudes can be 
promoted through strategic management such as developing a supportive culture that 
embraces changes aligned with the mission of the organization; secondly, invest in early 
adopters, who will be technology champions. A technology champion, especially the 
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professional with entrepreneurial-oriented mindset, is of critical importance in every 
phase for promoting technology adoption; Thirdly, management should empower 
employees by applying a bottom-up approach rather than solely a top-down approach in 
the process of product design and technology adoption/implementation; Fourthly, 
management should engage in extensively information sharing and interactions across 
organizations to promote a synergetic effect in the process, through for example, 
collaboration, corporation, educational seminar and courses. The successful cases are 
powerful in fostering a social environment for innovations. 
7. Further	Research	and	Limitations	
Although the findings from our in-depth study focusing on Oslo area is 
representative across the country, in order to draw a nationwide picture on PCM adoption, 
further investigation should be performed within the other three regions (Bergen, Tromsø 
and Trondheim), as well as collaboration and synergy between regions. The collaboration 
and synergy among regions will impact on the continued adoption and dissemination 
across country. Our current results show a limited collaboration towards clinical use 
within some regions. This was partly due to the different choice of technology 
infrastructure and associated difficulty of standardization and results comparison between 
different technologies. How to make the national platform work in its best synergy on 
this basis warrants further study.  
At present, a higher degree of adoption was observed in research environment 
comparing to that in clinical setting. The adoption in research is building up core 
competence for its translational clinical use. A follow-up qualitative research with 
prolonged time frame following a retrospective history of the adoption and diffusion, 
especially within clinical settings, will be essential for understanding this whole time-
dependent adoption process.  
While trying to provide exhaustive empirical data for the case, we are limited 
regarding to the theoretical research. We expect the information provided in this report to 
be useful for future expanded theoretical research.   
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9. Appendix	
 
1. Case study protocol: to make as many step as operational as possible to ensure 
reliability. 
Case Study Protocol: 
I. Introduction to the case study and purpose of protocol 
a. Case study research questions, and propositions 
b. Theoretical framework for the case study from literature review 
c. Role of the protocol in guiding study 
II. Data collection procedure. 
a. Select the nominations in the study, contact person and names of sites 
to be visited 
b. Data collection plan. Contact each informant via email and telephone 
to arrange a site visit. Informants are informed with the purpose of the 
case study and research questions. Interview questions are sent to 
informants beforehand. Conduct site visit. Audio record interview with 
interviewee’s agreement. Note-taking during interview.  Follow-up 
activities (thank-you letter and additional questions, if any). 
III. Prepare the case study composition.     
a. Transcribe and analyze the interviews  
b. Develop hypothetical logic model based on the relevant theoretical 
framework  
c. Outline the draft. 
IV. Specific set of questions were raised to individual informant based on the 
different involvement in the project.  
  
2. Case study database: to keep a good auditability so the same results will be 
produced if the same procedure is followed. The following table summarize the 
type of the data used in the study:  
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3. Interview Questions: 
Semi-structured interview method was used for collecting primary data for this 
research. This method allows researcher open to all-round perspectives from the 
stakeholders, while staying focused on the topic. Based on the role of each 
stakeholder in the PCM program, various questions were raised in the interview. 
These questions are listed below: 
 
Questions to leader of NSG: 
1. You have led a group suggesting “individualized cancer treatment for all 
Norwegian patients based on the gene profile of their own tumor”, which is 
the earliest national initiative for personalized cancer medicine (PCM). What 
is the rationale behind that initiative?   
2. What is the procedure of a sequencing analysis for clinical use? How long 
does it take in present practice? Is any perceived problem or inconvenience?  
3. As a doctor, what are the perceived bottlenecks for implementation of the 
system national wide? How is doctor involved in the process now? 
4. Is it difficult to explain to patient about the PCM concept? How could it be 
easier? How much do doctors need explain to them? 
5. What kind of informatics system/software would you like to have? What are 
the necessary features in the software? As one of the end-users, how do you 
involved in the development of the software? 
6. As a doctor, what kind of training related to PCM would you like to have? 
What kind of training has been initiated for doctors now?  
 
Questions to Coordinator of NSG: 
Unit Being Characterized Total System Intermediate Units Individuals
Issues, laws, policies, historical data Local history, documents, interview with leaders Interviews
and Convention reports
Norgwigain healthcare as a whole Structure, Institutional
Healthcare region and Hospitals Structure, Institutional Behavior properties, communication network Behavior properties and mindset
Governmental agency Structure, Institutional Behavior properties, communication network
Industry Structure, Institutional Behavior properties, communication network
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1. Within the PCM program, what is the activity scope we are focusing on 
towards both clinic and research? 
2. How is the program organized? How is industry partner involved? 
3. What are the challenges for you as a project coordinator? 
 
Questions to PCM program leader:  
1. Could you give a short introduction to the project? How was it initiated? 
2. What are the major milestones you have reached? What are the major 
challenges that you have encountered so far? How do you think they could be 
resolved? 
3. What type of technology platform/software you think that would work best for 
Norwegian system? Why? 
4. Adoption and implementation of such a complex innovative technology in the 
whole healthcare will require high degree fitness between human, technology, 
organization factors. What have been done in order to promote such fitness 
within and across organizations?  
 
Question to Industry partner/bioinformatician researchers: 
1. What type of technology platform/software you think that would work best for 
Norwegian system? Why? 
2. What kind of informatics system/software would you like to develop? What 
are the necessary features in the software? 
3. What are the major milestones you have reached and what are the major 
challenges that you have encounter so far? How is it possible to resolve them? 
4. Oncologist is one of the end users. How are they involved in the development 
of the software?   
      Questions to Biotechnology advisory board:  
1. Could you give a short introduction to the project and role of your 
organization in the project?  
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2. What are the major concerns for adopting PCM, from Bioteknologinemnda’s 
point of view? 
3. How well is the patient right pertaining to PCM protected in Norway? Are the 
laws/regulations in place for protecting patient’s right? What is missing, if any?  
4. In your opinion, do we have all the laws/regulations ready in order to adopt 
PCM? If not, in which area do we need additional work?    
5. What are the major milestones you have reached and what are the major 
challenges that you have encounter so far? How is it possible to resolve them? 
6. Recommendations for some public available documents regarding your work 
and achievement. 
Questions to Kreftforeningen: 
1. Could you give a short introduction to the project and role of kreftforeningen 
in the project?  
2. From your experience, how well does patient understand/accept the concept 
about gene, DNA sequencing? How do they perceive the predictive value of 
PCM? 
3. What are the major milestones you have reached and what are the major 
challenges that you have encounter so far? How is it possible to resolve them? 
Questions to Oslo Cancer Cluster: 
1. OCC coordinates PCM program. Could you give a short introduction to the   
program and role of OCC in the PCM?  
2. How are industry partners involved in the PCM project?  
3. What is the nature, if any, of collaborative effort across communities needed 
to put this project forward for technology adoption?  
4. What are the major milestones you have reached and what are the major 
challenges that you have encounter so far? How is it possible to resolve them? 
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Questions to molecular biologist, pathologists, oncologist: 
1. How do you use DNA sequencing technology in your work? How are you 
satisfied with the technology? 
2. What are the perceived values of PCM for you as a scientist? 
3. As an innovative scientist, how would you perceive the organizational 
attributes in Norwegian healthcare in terms of fostering innovation? 
  Questions to Cancer Registration: 
1. Could you give a short introduction to the role of cancer registration in the 
PCM program? 
2. What kind of challenges PCM is imposing on cancer registration? 
 
